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PATRICIA SHERWOOD BRIGHT. Studies of the Depolarization-Induced 
Release of Beta Adrenergic Receptor Blocking Drugs from in 
vitro Neural Preparations. (Under the direction of JERRY G. 
WEBB. ) 
The objective of this study was to evaluate the hypothesis that 
nerve terminals may serve as a site for storage and release of beta 
adrenergic receptor blocking drugs. Experiments were conducted with 
two different in vitro neural preparations, cultured superior cer-
vical ganglia from adult rats and synaptosomes prepared from rat 
cerebral cortex. The release of propranolol by depolarizing stimuli 
was examined and compared with the release of the more hydrophilic, 
cardioselective beta receptor antagonist atenolol. In both neuronal 
models, norepinephrine release was monitored as an index of exocy-
tosis. 
Cultured superior cervical ganglia of the rat represent an in 
vitro model for adrenergic neurons which contains no post junctional 
effector tissue. Ganglia excised from adult rats and maintained in 
a chemically defined media for 48 hours develop axonal sprouts that 
have uptake, storage and release mechanisms characteristic of sympa-
thetic nerve endings. Electrical field stimulation of 48-hour 
cultured ganglia preloaded with either 3H-propranolol or 3H-norepi-
nephrine was found to promote the release of each molecule in a 
frequency-dependent manner. Stimulation for 30 seconds at a frequency 
of 15 Hz released 3.00% of the norepinephrine and 0.15% of the 
propranolol accumulated by the ganglia. Removal of extracellular 
calcium and elevation of magnesium reduced the stimulation-induced 
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release of norepinephrine (control = 161 ± 31 fmol/3D sec/ganglion) 
by 60% but did not affect the stimulation-induced release of pro-
pranolol (control = 17 ± 5 fmol/30 sec/ ganglion). Norepinephrine 
release was also inhibited by bretylium and enhanced by phenoxybenz-
amine, whereas neither agent altered the stimulation-induced release 
of propranolol. Moreover, reserpine pretreatment almost abolished 
norepinephrine accumulation and release without affecting the accumu-
lation or release of propranolol. These results demonstrate that 
propranolol is released from neural tissue in response to electrical 
stimulation. In addition, the data indicate that propranolol release 
from cultured ganglia occurs by a different mechanism than that 
observed for norepinephrine and appears to result from a calcium-
independent, presumably nonexocytotic, process. 
Synaptosomes were prepared by discontinuous sucrose density 
gradient centrifugation and used as a model of isolated nerve termi-
nals. When incubated at 30°C with radiolabelled drugs (0.1 ~M), 
synaptosomes accumulated 20 pmoles propranolol and 0.6 pmoles 
atenolol/mg protein. Exposure of 3H-propranolol-loaded synaptosomes 
to elevated potassium, rubidium or cesium was found to evoke a 
concentration-dependent increase in drug efflux. The action of 
these ions to release propranolol was highly correlated with their 
ability to produce synaptosomal membrane depolarization as estimated 
with the voltage-sensitive dye diS-C
3
-(S). When external potassium 
was increased to 75 mM, 25% of the propranolol accumulated by the 
synaptosomes was released within 15 seconds. Elevated external 
potassium also promoted the efflux of 3H-atenolol from preloaded 
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synaptosomes, with 75 mM potassium releasing in three minutes 25% of 
the atenolol taken up. 3H-Norepinephrine was released by potassium 
with a time course similar to that found for atenolol. Depolariza-
tion of synaptosomes with veratridine was also observed to stimulate 
the release of both propranolol and atenolol and these effects were 
antagonized by tetrodotoxin. Under calcium-free conditions, 
potassium-induced release of propranolol was reduced 37% while 
atenolol release was decreased 68% and norepinephrine release 82%. 
Pretreatment of rats with 6-hydroxydopamine to destroy adrenergic 
nerve terminals failed to alter the steady state accumulation or the 
potassium-induced release of either propranolol or atenolol from 
synaptosomes. The results from these studies demonstrate that both 
polar and nonpolar beta receptor antagonists are accumulated by 
nerve endings and released in response to membrane depolarization. 
The data also raise the possibility that these drugs may be released 
from nonadrenergic as well as adrenergic neurons. 
The depolarization-induced release of propranolol from cultured 
sympathetic ganglia and synaptosomes is consistent with previous 
findings of propranolol release in association with sympathetic 
nerve stimulation in situ. The release of atenolol extends these 
observations to include polar beta receptor antagonists as well as 
the lipophilic propranolol molecule and suggests that this phenom-
enon may apply to the entire class of these drugs. While atenolol 
release has the characteristics of an exocytotic event, propranolol 
release from these preparations appears to be complex and may involve 
a combination of exocytotic and nonexocytotic mechanisms. The 
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results of the present study support the concept that neural storage 
and release of beta adrenergic receptor blocking drugs may contribute 
to their pharmacological actions by modulating drug concentration at 




The concept of two different adrenergic receptor populations, 
designated as alpha and beta, was introduced by Ahlquist in 1948. 
In that study, it was shown that a series of six sympathomimetic 
amines differed in their potencies to stimulate or inhibit a variety 
of sympathetic effector tissues. Alpha receptors were associated 
with many of the excitatory functions of the sympathetic nervous 
system (vasoconstriction, contraction of the radial muscle of the 
eye, the uterus, nictitating membrane and ureter) and one inhibitory 
function (intestinal relaxation). Beta receptors were associated 
with most of the inhibitory functions (vasodilation and relaxation 
of the uterus and bronchial smooth muscle) and one excitatory 
function (myocardial stimulation). Beta receptor activation addi-
tionally produces other stimulatory responses in kidney, pancreas 
and salivary glands that result in increased secretion of renin, 







receptors were associated with 
cardiac stimulation and lipolysis, while beta2 receptors were respon-
sible for vascular and bronchial dilation (Lands et al., 1967). In 
the 1970's, alpha receptors were also differentiated into two sub-
classes, alpha} and alpha
2
, on the basis of their location, function 
and pharmacological selectivity. Postsynaptic receptors mediating 




receptors were originally proposed to exist only 
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on nerve terminals and t.o regulate neurotransmitter release presynap-
tically (Langer, 1974), but have since been found postsynaptically 
on effector tissue as well where their function is not completely 
understood. 
The concept of multiple forms of adrenergic receptors was 
strengthened by the introduction of selective antagonists. Dibena-
mine, a synthetic agent shown to block excitatory responses of 
smooth muscle to sympathetic nerve stimulation and to epinephrine, 
represented one of the first alpha adrenergic blocking drugs 
(Nickerson and Goodman, 1947). The actions of the first compound to 
block beta receptors, dichloroisoproterenol, were described in 1958 
by Powell and Slater. Dichloroisoproterenol antagonized the inhibi-
tory actions of the sympathomimetic amines epinephrine and isopro-
terenol on blood pressure and on uterine and bronchial smooth muscle. 
The first report of specific adrenergic blockade of the mammalian 
heart was also published in 1958 when it was shown that dichloroiso-
proterenol selectively inhibited the positive inotropic and chrono-
tropic effects of the adrenergic stimuli epinephrine, norepinephrine 
and isoproterenol as well as electrical stimulation of cardiac 
sympathetic nerves (Moran and Perkins, 1958). 
The suggestion by Black and Stephenson (1962) that blockade of 
beta adrenergic receptors should reduce myocardial demand for oxygen 
and thus be useful in the management of angina pectoris stimulated 
the search for effective beta blockers other than dichloroisopro-
terenol which had been shown to possess intrinsic sympathomimetic 
actiyity and therefore was not a good candidate for the treatment of 
cardiac disorders. Beneficial effects of pronethalol, a drug 
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relatively free of intrinsic sympathomimetic activity, were demon-
strated in the treatment of angina (Dornhors t and Robinson, 1962; 
Prichard et al., 1963) and cardiac arrhythmias (Stock and Dale, 
1963). A hypotensive effect of pronethalol was also observed in 
angina patients in 1964 (Prichard, 1964); however, the usefulness of 
pronethalol was questioned because it was found to be carcinogenic 
in mice (Paget, 1963). The first report on the pharmacological 
actions of propranolol was published in 1964 (Black et al., 1964). 
In this study, propranolol was found to be ten times more potent 
than pronethalol in inhibiting both inotropic and chronotropic 
responses in the preparations studied. Moreover, results from 
preliminary clinical studies of the drug suggested that propranolol 
would be useful in the treatment of angina pectoris (Hamer et al., 
1964) and hypertension (Prichard and Gillam, 1964), a finding sub-
sequently confirmed in long term studies conducted with a larger 
population of patients (Warren et al., 1976; Prichard and Gillam, 
1969). Research in the past 15 years has been directed toward 
developing beta receptor blocking drugs with modified molecular 
structures to reduce the incidence of unwanted side effects. From 
this work have come selective antagonists for the beta2 receptor such 
as butoxamine and the cardioselective beta
1 
receptor antagonists 
such as practolol, metoprolol and atenolol. 
Therapeutic Uses and Actions of Beta Adrenergic Receptor Antagonists 
Beta adrenergic receptor antagonists are widely used thera-
peutically as evidenced by their rankings in the 200 most prescribed 
drugs of 1983. Propranolol was ranked as the most prescribed drug 
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of 1983 while the other beta blocking drugs metoprolol, atenolol and 
nadolol were also listed at ranks of 19, 28 and 47, respectively. 
In each case, the number of prescriptions written for each of these 
beta blockers increased in 1983 over 1982 (American Druggist, 1984). 
Propranolol, as the prototype beta adrenergic receptor antagonist, 
is currently used in the treatment of a number of cardiovascular 







Medical Letter, 1982) cardiac arrhythmias 
and hypertension (Prichard et al., 1977; 
Fitzgerald, 1980). Propranolol is also employed in the prophylactic 
treatment of migraine (Mathew, 1981) and is currently being evaluated 
for its usefulness in the treatment of schizophrenia (Peet, 1981). 
Despi te the widespread use and therapeutic benefi ts of beta 
receptor antagonists, the mechanism by which these drugs produce 
their effects is often unclear. Members of the drug class differ in 
terms of their potencies in producing beta receptor blockade, in the 
degree of intrinsic sympathomimetic activity exhibited, in their 
physicochemical properties and in their ability to produce non-beta 
receptor-mediated actions, such as membrane stabilization (Table 
1). The extent that each of these components contributes to a given 
therapeutic effect appears to vary and several criteria have been 
established to assess this question. An important comparison involves 
determining the relative potency of stereoisomers in producing an 
effect. In the case of propranolol, the l-isomer is 60-100 times 
more potent as a receptor antagonist than the d-isomer (Howe and 
Shanks, 1966; Barrett and Cullum, 1968), and for any action resulting 
from beta receptor blockade, I-propranolol should be substantially 
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more potent than d-propranolol. Comparisons between dose and time 
of onset required for an effect have also been useful in assessing 
the relative contribution of beta blocking and non-beta blocking 
properties of these drugs. Studies of beta receptor antagonists 
with differing physicochemical properties are also helpful in that 
when lipophilicity is a key determinant of a drug effect, non-beta 
receptor blocking actions appear to playa major role. In studies 
of the mechanism of action of beta receptor antagonists, one or more 
of these comparisons are generally made to help elucidate those 
properties of the molecule that contribute to a demonstrated effect. 
Angina Pectoris 
Angina pectoris occurs when myocardial oxygen demand exceeds 
supply which has been limited by the narrowing of coronary arteries. 
The rationale for using propranolol in the treatment of angina is 
that it decreases myocardial oxygen demand by decreasing heart rate, 
contractility and systemic arterial pressure (Shand, 1975; Cohen, 
1978). Further actions of propranolol on the coronary circulation 
are its effects to increase perfusion of the subendocardium (Gross 
and Winbury, 1973) and maintain perfusion to ischemic regions (Pitt 
and Craven, 1970). The principal beneficial effect, however, results 
from the oxygen-sparing actions of propranolol to decrease heart 
rate and contractility_ 
The underlying mechanism of action of propranolol in the treat-
ment of angina is clearly related to beta receptor blockade. The 
d-isomer of the drug is ineffective in improving exercise tolerance 
in angina patients (Wilson et al., 1969) or in decreasing the number 
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of anginal attacks (Bjorntorp, 1968). Membrane stabilization also 
does not appear to be a requirement for antianginal drugs because 
drugs with no membrane stabilizing effects, such as practolol, 
remain effective in the treatment of angina (Wilson et al., 1969; 
Prichard, 1974). 
Myocardial Infarction 
Myocardial infarction refers to death of myocardial tissue that 
has resulted from the insufficiency or absence of blood supply. 
Propranolol has been used in the management of patients after myo-
cardial infarction. In a long term multicenter study conducted by 
the National Heart, Lung and Blood Institute, propranolol was shown 
to reduce the mortality of postinfarction patients by 26.5% (JAMA, 
1982). The mechanism of propranolol t s action in producing this 
effect is unknown at this time. Other beta receptor antagonists 
that have been tested and also found effective for use after myocar-
dial infarction include timolol and metoprolol (Medical Letter, 
1982). 
Cardiac Arrhythmias 
Arrhythmias occur because of an alteration in automaticity 
and/or conduction of the cardiac impulse. Abnormalities in auto-
maticity affect the rate, regularity or the site of origin of the 
beat. A disturbance in conduction affects the normal sequence of 
activation of the atria or ventricles. Propranolol is used in the 
treatment of cardiac arrhythmias because it decreases sinus rate, 
decreases the spontaneous rate of depolarization of ectopic pace-
makers and slows conduction across the atrioventricular node. 
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AlLhough the antiarrhythmic effects of propranolol have been 
attributed to its actions to block beta adrenergic receptors, other 
of the drug's activities such as local anesthetic effects or membrane 
stabilization (Langslet, 1970) or its action to alter ion permability 
(Wu and Narahashi, 1973) may contribute to its effectiveness as an 
antiarrhythmic agent (Nies and WoosleYt 1978). There have been a 
number of reports which demonstrated a discrepancy between the dose 
of propranolol required for beta blockade and that required to exert 
antiarrhythmic effects. Propranolol doses that produced beta block-
ade in Purkinj e fibers were found insufficient to revert ouabain-
induced arrhythmias in this preparation (Pruett et al., 1977). 
Similarly, plasma levels of propranolol higher than those needed for 
the maximal reduction in exercise-induced tachycardia (40-100 ng/ml 
(Coltart and Shand, 1970)) were required by nine of 24 patients to 
reduce chronic ventricular arrhythmias (Woosley et al., 1979). 
Participation of a non-beta receptor blocking mechanism in the 
antiarrhythmic action of propranolol also is suggested by evidence 
that the N, N-dimethyl analogue of propranolol which lacks beta 
receptor blocking activity was nonetheless an effective antiarrhyth-
mic in dogs (Patterson et al. t 1980) and in five of seven patients 
with chronic ventricular arrhythmias (Reele et al., 1982). 
Hypertension 
In hypertension, many mechanisms have been proposed for the 
antihypertensive actions of beta receptor antagonists. Some of the 
more prominent have included the reduction of cardiac output, 
decreased renin secretion, a centrally-mediated decrease in sympa-
thetic nervous system activity and attenuation of neurotransmitter 
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release resulting from a direct interaction of drug with adrenergic 
neurons (Schriabine, 1979). None of these mechanisms, however, by 
itself has served to provide a unifying hypothesis to explain the 
antihypertensive effects of beta blocking drugs as a class. 
Reduction in cardiac output as the major mechanism of the 
antihypertensive action of beta blocking drugs is discredited by the 
following findings. There is a lack of a close temporal relationship 
between the reduction in cardiac output and the reduction in arterial 
pressure. Propranolol lowers cardiac output rapidly while its 
effects on arterial pressure are gradual, sometimes taking six to 
eight weeks for the maximal effect to develop (Prichard and Gillam, 
1969). Moreover, the doses of drug required for beta blockade and a 
reduction in cardiac output are lower than those generally required 
for a reduction in arterial pressure (Shand, 1974). The propranolol-
induced reduction in cardiac output also does not correlate well 
with its antihypertensive effectiveness (Tazari et al., 1976). In 
addition, beta blockers that have little or no effect on cardiac 
output because they possess intrinsic sympathomimetic activity, such 
o 
as bunitrolol (Baum et al., 1971) and alprenolol (Ablad et al., 
1967) , nonetheless lower arterial pressure. Taken collectively, 
these data suggest that although reduction in cardiac output may 
contribute to the antihypertensive action of some beta blockers, it 
is not the sole mechanism by which beta receptor antagonists as a 
class reduce arterial pressure. 
The proposal that inhibition of renin secretion represents the 
principal mechanism of antihypertensive action of beta adrenergic 
blocking drugs suffers from the same limitations as those described 
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for cardiac output; that is, there are discrepancies between the 
times of onset and doses required to reduce plasma renin activity 
and to decrease arterial pressure. For example, Amery et al. (1976) 
in evaluating the effects of propranolol in doses ranging from 
60-480 mg/day found the 60 mg/day dose of propranolol maximally 
reduced plasma renin concentration while propranolol decreased blood 
pressure in a dose-dependent manner. Indeed, in sufficient dosage 
propranolol is capable of reducing blood pressure in a broad range 
of hypertensive patients including those with initially low plasma 
renin activity (Hollifield et al., 1975). Thus, while it is clear 
that propranolol-induced reduction of plasma renin activity may 
represent a key factor in reducing blood pressure of patients with 
high renin hypertension (Buhler et al., 1972), this does not appear 
to represent a general mechanism of action for beta receptor blocking 
drugs in most cases of essential hypertension. 
The proposal that beta blockers may act through a central 
mechanism to lower arterial pressure has been based principally on 
the observation that direct administration of these drugs into the 
brain decreases blood pressure (Kelliher and Buckley, 1979; Privitera 
et al., 1979). However, the more hydrophilic beta receptor blockers 
tend to penetrate the central nervous system poorly but are still 
effective antihypertensive drugs. When administered intravenously 
or into the left vertebral artery of anesthetized cats, the lipophilic 
metoprolol and the more hydrophilic atenolol had hypotensive and 
bradycardic activities that were similar in magnitude and time of 
onset while the extent of their accumulation into CSF and brain 
differed six to nine-fold (Van Zwieten and Timmermans, 1979). In 
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addition, d-propranolol which is equipotent to the I-isomer in 
reducing arterial pressure when administered centrally 1S ineffec-
tive as an antihypertensive agent in man (Rahn et al., 1974). Thus, 
it is difficult to support a central action as the primary mechanism 
by which beta receptor antagonists as a class lower blood pressure. 
It has also been proposed that beta blockers exert their anti-
hypertensive action by inhibiting sympathetic nervous system trans-
mission. Propranolol has been shown to inhibit responses of sympa-
thetically-innervated smooth muscle preparations (e.g., rabbit ear 
artery and rat vas deferens) to field stimulation (Day et al., 1968; 
Barrett and Nunn, 1970), presumably the result of actions of the 
drug at the adrenergic nerve endings to decrease norepinephrine 
release. A reduction in norepinephrine release from field-stimulated 
guinea pig vas deferens was demonstrated by Saelens and coworkers 
(1977) and again an interaction of the drug with the adrenergic 
nerve terminal was suggested. Conceivably, propranolol may act to 
block presynaptic beta receptors and inhibit the proposed positive 
feedback modulation of neurotransmitter release (Adler-Graskinsky 
and Langer, 1975) to diminish norepinephrine output. Observations 
in man tend to argue against this hypothesis in that many studies 
have demonstrated an actual increase in plasma norepinephrine levels 
in patients receiving therapeutic doses of beta receptor blocking 
drugs (Rahn et a1., 1978; Morganti et al., 1979). Interpretation of 
these data is complicated, however, by the findings that beta receptor 
antagonists can cause reflex changes in sympathetic tone as well as 
influence catecholamine clearance from plasma (Esler et al., 1981). 
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In spite of these numerous proposals to explain the effects of 
beta receptor antagonists on arterial pressure, the mechanism of 
their antihypertensive action must still be considered unknown. 
Conceivably, the antihypertensive mechanism of these drugs may 
involve a combination of the actions discussed above. The particular 
combination may vary depending on the properties of the individual 
molecule. It is equally possible that an unrecognized action of 
beta receptor blocking drugs may ultimately prove to be the critical 
determinant of their antihypertensive effects. 
Migraine 
Migraine is a type of vascular headache that involves changes 
in both intracranial and extracranial vessels. Although the patho-
physiology of migraine is not completely understood, both vasocon-
striction and vasodilation appear to be involved in the proposed 
sequence of events that result in migraine (Diamond and Medina, 
1981). Stress or other factors induce both neurogenic stimulation 
of cerebral arteries and the systemic release of 5-hydroxytryptamine 
(S-HT) which results in vasoconstriction. In response to the anoxia 
and acidosis caused by the decreased blood supply, the cerebral 
vessels dilate. The amount of dilation of the cranial vessels is 
related to the intensity of a migraine attack (Wolff, 1963). This 
vasodilation may be mediated by beta
2 
receptors or may represent a 
response resulting from S-HT reduction. 
Propranolol has been used in the prophylactic treatment of 
migraine (Wideroe and Vingander, 1974; Mathew, 1981). It has been 




receptors (Wideroe and Vingarder, 1974). Pro-
pranolol's interaction with 5-HT systems may also contribute to its 
therapeutic effect. Both d- and dl-propranolol, at a concentration 
of 1.0 ~M, have been reported to inhibit 5-HT transport into platelets 
(Rudnick et al., 1981), an action that might prolong 5-HT vasocon-
striction and prevent subsequent vasodilation. Alternatively', 
propranolol, a reported antagonist of both 5-HT1 receptors (Middle-
miss et al., 1977) and 5-HT
2 
receptors (Green et al., 1983) may 
prevent th~ initial serotonin-induced vasoconstriction that contri-
butes to the events leading to migraine. 
Schizophrenia 
Schizophrenia is a type of psychosis characterized by delusions, 
hallucinations and extensive withdrawal of the individual's interest 
from other people and the outside world. Propranolol has been shown 
to be effective in the treatment of schizophrenia (Hanssen et al., 
1980). The findings that the d-isomer produced a significant improve-
ment in seven out of nine schizophrenic patients (Hirsch et al., 
1981) and that high daily doses of the drug, usually one gram or 
more, are required for an effect raise the possibility that a non-
beta receptor mediated mechanism may be involved. 
In summary, the mechanisms of action of beta receptor antag-
onists in the treatment of numerous disorders remain unclear after 
more than 20 years of intensive investigation. While beta receptor 
blockade is clearly a component of the effect of these drugs in 
most, if not all, cases, a significant role must also exist for 
non-beta receptor mediated actions or beta receptor mediated effects 
not previously considered or understood. 
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Interactions of Propranolol with Adrenergic Neurons 
Influences of beta adrenergic receptor antagonists on the 
activity of the sympatheti~ nervous system could contribute to each 
of the therapeutic effects of these drugs. Propranolol has been 
shown to interact with adrenergic nerve endings in a variety of 
sympathetically innervated tissues (Daniell et al., 1976; Saelens et 
al., 1977) as well as the adrenal medulla (Sugarawa et a1., 1980) 
and brain (Tackett et al., 1981). In the heart, propranolol admin-
istration into the anterior descending branch of the left coronary 
artery of the dog caused a localized increase in contractile force, 
an effect which was associated with an enhanced overflow of nor-
epinephrine from the heart and which was blocked by pretreatment 
with reserpine (Daniell et al., 1976). Saelens et a1. (1977) found 
that propranolol also enhanced the spontaneous efflux of tritium 
from adrenergic nerve endings prelabelled with 3H-norepinephrine in 
the isolated guinea pig vas deferens; however, most of the tritium 
that was released was identified as deaminated metabolites of nor-
epinephrine. Propranolol had no effect on the spontaneous efflux of 
dopamine-~-hydroxylase. Thus, propranolol-induced release of nor-
epinephrine from nerve endings does not appear to be due to an 
enhancement of exocytosis wherein most of the norepinephrine would 
be released intact and accompanied by other soluble contents of the 
synaptic vesicle such as dopamine-~-hydroxylase, but rather appears 
to result from displacement of norepinephrine directly from storage 
vesicles into the cytoplasm where a large fraction of neurotrans-
mitter is metabolized prior to leaving the cell. Propranolol when 
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administered intravenously in rat was also found to release epineph-
rine and norepinephrine from the adrenal gland (Sugarawa et a1", 
1980). In addition, Tackett et al. (1981) reported that propranolol 
perfused directly into the: cerebroventricular system released nor-
epinephrine in the brain as reflected by changes in cerebrospinal 
fluid levels of transmitter. 
These findings, taken collectively, support the hypothesis that 
propranolol may enter the adrenergic nerve terminal and interact 
directly with storage vesicles in such a manner as to promote the 
release of endogenous norepinephrine and raise the possibility that 
propranolol might be actively accumulated by adrenergic nerve endings. 
Initial studies on the mechanism of accumulation of propranolol into 
adrenergic ~eurons suggested that the drug might be a substrate for 
the biogenic amine transport system. Pretreatment with imipramine, 
an inhibitor of the amine uptake system, antagonized the increase in 
contractile force induced by the intracoronary injection of propran-
olol in the dog heart (Daniell et al., 1976). Accumulation of 
propranolol into cultured superior cervical ganglia of the rat was 
also inhibited by imipramine, but further studies demonstrated that 
cocaine and ouabain, also inhibitors of active amine transport, had 
no effect on propranolol accumulation by this adrenergic tissue 
(Saelens et al., 1977). From these data it was concluded that 
propranolol is not a substrate for the biogenic amine uptake system 
and that the antagonism of propranolol accumulation by imipramine 
may represent a competition between imipramine and propranolol for 
binding sites in cellular membranes (Dollery and Junod, 1976; Rudnick 
et al., 1981). 
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Subsequent to the demonstration of propranolol accumulation in 
adrenergic neurons, studies were conducted to determine if the drug 
itself was released in response to nerve stimulation. In dogs 
pretreated orally with propranolol for seven days, stimulation of 
the cardiac accelerator nerves was observed to release both propran-
olol and norepinephrine from the heart as determined by changes in 
coronary sinus concentrations and elevated venoarterial differences 
for each of the substances (Daniell et al., 1979). The indirect-
acting sympathomimetic amine tyramine also provoked the simultaneous 
release of propranolol and norepinephrine from this peparation. In 
contrast, isoproterenol, a drug that acts at postj unctional beta 
receptors to cause direct myocardial stimulation, failed to stimu-
late propranolol overflow. These data suggested that propranolol 
was being released by nerve stimulation or by tyramine from the 
presynaptic cardiac nerve ending and that the release of propranolol 
was not a result of its displacement from post junctional beta recep-
tors or increased myocardial stimulation. 
Nerve stimulation-induced release of propranolol was also 
demonstrated at other adrenergic neuroeffector junctions including 
the dog hindlimb and spleen (Russell et al., 1983). In both tissues 
activation of sympathetic innervation increased the overflow of 
propranolol with a time course that paralleled norepinephrine release. 
In the spleen, the venous arterial difference of propranolol increased 
as much as 100 ng/ml during the stimulation period. In the hindlimb, 
intraarterial injection of phenylephrine in a dose sufficient to 
produce vasoconstriction equivalent to that observed during nerve 
stimulation also caused an increased efflux of propranolol in the 
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absence of an increased overflow of norepinephrine. Moreover, prior 
administration of prazosin, a selective alpha} receptor antagonist, 
inhibited the stimulation-induced release of propranolol by 75%. 
Thus, in the hindlimb, a significant amount of propranolol released 
in association with nerve stimulation appears to arise from post-
synaptic sites, the result of activation of alpha} receptors and 
contraction of vascular smooth muscle. 
These experiments have demonstrated the release of propranolol 
upon activation of adrenergic neurons at a number of sites including 
the heart, the peripheral vasculature and the spleen. It appeared 
that propranolol was released from postsynaptic effector tissue as 
well as presynaptic neural tissue. The fraction of propranolol 
released from presynaptic and postsynaptic sites, however, was found 
to vary in two tissues. In the heart, propranolol release occurred 
principally from presynaptic sites while in the hindlimb a substantial 
fraction of the propranolol was released from post junctional effector 
tissue. 
The observation that propranolol accumulates in adrenergic 
neurons for release upon nerve stimulation may have several impli-
cations regarding the drug's actions. Nerve stimulation represents 
a mechanism by which the accumulated propranolol can be delivered 
from the nerve ending directly into the synapse. Once in the synapse, 
the drug would be available to reinforce beta blockade at pre- or 
postsynaptic receptors. Blockade of presynaptic beta receptors on 
noradrenergic neurons could inhibit the proposed positive feedback 
modulation of neurotransmitter release (Adler-Graskinsky and Langer, 
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1975) and thereby diminish norepinephrine output. Such a storage 
and release mechanism for propranolol from neurons might explain, in 
part, the general lack of a close relationship between plasma levels 
of propranolol and certain of its therapeutic effects (Prichard, 
1977) as well as the reported persistence of propranolol's effect on 
heart rate after plasma levels of drug have decreased below effective 
concentrations (Leaman et al., 1976). Moreover, propranolol release 
from nerve endings directly into the synaptic cleft may result in 
high localized concentrations of drug at the cell surface and result 
in enhanced pharmacological effects not generally expected from the 
concentrations of propranolol found in plasma. For example, pro-
pranolol in high concentrations has been shown to antagonize sodium 
(Matthews and Baker, 1982) and calcium movements (Noak et al., 
1979), alter prostaglandin production (Jackson and Campbell, 1981) 
and alter membrane phospholipid metabolism (Pappu and Hauser, 1981a; 
1981b; Pappu and Hauser, 1982). The consequence Pappu and Hauser, 
of these effects could be to alter neurotransmitter release or to 
modify the post junctional responses to the neurotransmitter. 
Objectives and Aims 
The accumulation and release of propranolol at adrenergic 
neuroeffector junctions presents a novel mechanism which could 
contribute to the pharmacokinetic and pharmacodynamic actions of 
propranolol and perhaps other beta adrenergic receptor antagonists. 
However, the in situ studies in the dog have not clearly demonstrated 
the degree that propranolol release may occur from nerve endings nor 
have the mechanisms of release been examined. Moreover, whether 
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such release occurs for other beta receptor blocking agents remains 
unknown. The objectives of the present studies were to extend the 
findings of the in situ experiments by using model neural preparations 
to determine whether propranolol release from neurons could be 
demonstrated in vitro and, if so, to evaluate the release mechanisms 
involved and to compare the release of propranolol with that of 
other beta receptor blocking drugs. 
Specific Aims: 
1. To examine field stimulation-induced release of propranolol 
from cultured superior cervical ganglia of the rat and to 
determine whether the release mechanism is identical to 
that established for norepinephrine (i. e., exocytosis)" 
2. To examine propranolol release from rat brain synaptosomes 
by veratridine or elevated concentrations of alkali metal 
ions and to determine whether its release is the result of 
membrane depolarization. 
3" To evaluate the effects of divalent cations and drugs 
known to influence exocytotic secretion on the depolari-
zation-induced release of propranolol and norepinephrine 
from rat brain synaptosomes. 
4. To determine if beta adrenergic receptor antagonists with 
different physicochemical properties than propranolol are 
also accumulated and released from nerve endings. 
CHAPTER II 
FIELD STIMULATION-INDUCED RELEASE OF PROPRANOLOL 
FROM CULTURED SUPERIOR CERVICAL GANGLIA OF THE RAT 
INTRODUCTION 
Superior cervical ganglia excised from adult rats consist of 
preganglionic cholinergic nerve terminals, cell bodies of sympa-
thetic neurons and postganglionic sympathetic axonal processes. In 
addition, nonneural supporting elements such as Schwann cells and 
glia are also present (Kopin et al., 1973). Ganglia removed from 
adult rats can be maintained in an artificial culture media in vitro 
for up to one week. During this time the neurons retain the ability 
to respond to acetylcholine (Larabee, 1970). In addition, normal 
levels of the catecholamine biosynthetic enzymes tyrosine hydroxy-
lase (MacKay and Iverson, 1972) and dopamine-beta-hydroxylase are 
maintained for at least four days along with a normal rate of nor-
epinephrine biosynthesis (Silberstein et al., 1972a; Webb et al., 
1975). Shortly after being placed in cuI ture, ganglia undergo 
degeneration of the severed pre- and postganglionic processes and 
begin to develop axonal sprouts which bud from the perikarya of the 
adrenergic nerve cells (Silberstein et a1., 1971).. At 48 hours, 
these sprouts are 10-25 microns in length and exhibit normal axonal 
organelles such as mitochondria, microtubules and a small number of 
.... 
large granular vesicles (Silberstein et a1., 1972b) .. Moreover, 
these processes are capable of innervating sympathetic effector 
tissues juxtaposed to the ganglia in culture (Silberstein et a1., 
1971; Olson and Malmfors, 1970). 
22 
Upt.ake of norepinephrine by isolated ganglia increases with 
time in cuI ture. This enhanced uptake reaches a maximum (four to 
six times that observed in freshly removed ganglia) within 48 hours 
and coincides with the development of the axonal sprouts (Silberstein 
et al., 1972b) _ Electron microscopic autoradiographic examination 
of ganglia cultured for 48 hours and then incubated with 3H-norepin-
ephrine revealed that 90% of the radioactivity taken up was asso-
ciated with these sprouting axonal processes (Silberstein et a1., 
1972b). Storage of neurotransmitter under these conditions was 
inhibited by reserpine pretreatment (Silberstein et a1 .. , 1972b). 
The accumulation of 3H-norepinephrine into the cultured superior 
cervical ganglia was characterized by Hanbauer and co-workers (1972) 
who reported that the uptake mechanism for norepinephrine into the 
newly formed axonal sprouts was similar to the uptake mechanism for 
norepinephrine by sympathetic nerve endings both kinetically (Km = 
1.9 x 10- 6 M) and pharmacologically as demonstrated by its sensi-
tivity to uptake inhibitors including cocaine, desipramine, metar-
aminol and ouabain. 
3H-Norepinephrine accumulated by cultured ganglia can be released 
by both elevated potassium (50 mM) and electrical field stimulation 
(Vogel et a1., 1972).. Field stimulation-induced release of neuro-
transmitter is calcium-dependent and is influenced in a predictable 
manner by pharmacological interventions. For example, Vogel et al. 
(1972) demonstrated that norepinephrine release from cultured superior 
cervical ganglia of the rat was reduced by bretylium, an adrenergic 
neuronal blocking drug, and enhanced by phenoxybenzamine, an alpha 
adrenergic blocking drug thought to inhibit negative feedback control 
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of neurotransmitter release (Langer, 1977). Moreover, the existence 
in cultured ganglia of presynaptic beta receptors that have the 
capability to modulate neurotransmitter release has also been reported 
(Weinstock, et al., 1978). Isoproterenol, a beta receptor agonist, 
was found to increase the potassium-induced (75 roM) release of 
norepinephrine from this preparation by 20-25%. While propranolol 
alone had no effect on potassium-induced norepinephrine release, it 
did block the enhanced norepinephrine release produced by isopro-
terenol. Such responses of norepinephrine release to drugs and 
ionic alterations indicate that neurotransmitter release from the 
axonal sprouts of cultured ganglia has the characteristics of that 
found in mature sympathetic nerve terminals. 
The composite of these observations indicates that the axonal 
sprouts of sympathetic ganglia maintained in organ culture possess 
the uptake, storage and release mechanisms characteristic of the 
varicosities of adrenergic nerve endings. This preparation, there-
fore, presents an opportunity to examine the interactions of beta 
receptor blocking drugs with adrenergic neural elements in the 
absence of post junctional effector tissue. Propranolol uptake by 
the cultured superior cervical ganglia of the rat was examined 
previously by Saelens et a1. (1977). The accumulation of pro-
pranolol in 48-hour cultured ganglia was found to be time-dependent 
and reached a concentration of 9.0 pmol/mg tissue after 60 minutes of 
incubation which represented a concentration of drug by the ganglia 
90-fold over that present in the incubation media. The time course 
of propranolol accumulation was slow to reach equilibrium, and 
steady state levels of propranolol were not attained by 60 minutes. 
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Investigation of the uptake mechanism revealed that although imipra-
mine inhibi ted propranolol accumulation into the cuI tured ganglia, 
cocaine and ouabain did not affect accumulation. These data 
suggested that the drug was not a substrate for the biogenic amine 
transport system and that the imipramine antagonism of propranolol 
uptake was not due to its actions on amine transport but likely 
represented an interaction between imipramine and propranolol within 
the cell membrane. A similar interaction between propranolol and 
imipramine has been reported for lung tissue (Dollery and Junod, 
1976) and may reflect 
propranolol and other 
a general phenomenon that 
lipophilic amines (Vestal 
Hemsworth and Street, 1981; Rudnick et a1., 1981). 
exists between 
et a1 .. , 1980; 
Initial studies to investigate the release of propranolol from 
cultured superior cervical ganglia demonstrated that both the 
indirect acting sympathomimetic amine, tyramine, and the membrane 
depolarizing agent, veratridine, could release propranolol in a 
concentration-dependent manner (Daniell et a1 .. , 1979). However, 100 
IJM tyramine was required to significantly increase the efflux of 
propranolol as compared to controls. The magnitude of the tyramine-
induced release represented approximately 2.5% of <the total propran-
olol accumulated by the ganglia. Moreover, 10 IJM veratridine was 
required to release approximately 2.0% of the total propranolol 
accumulated. The fact that a relatively high concentration of each 
of these amines was required to promote propranolol release from the 
ganglia raised .. the possibility that the release observed may not 
have been a result of specific actions of these drugs but may possibly 
represent effects to displace propranolol from cellular membranes. 
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Indeed, it is now clear that veratridine can release propranolol 
from nerve endings by a mechanism unrelated to membrane depolariza-
tion (see Chapter III). 
In the present study, experiments were designed to determine if 
propranolol could be released from cultured superior cervical ganglia 
of the rat in response to electrical field stimulation, a method of 
stimulation that more closely resembles physiological conditions 
and, if so, to examine the nature of the release mechanism involved. 
Interventions known to influence the exocytotic release of neuro-
transmi tter, such as, 1 ) alterations in extracellular calcium, 2) 
bretylium, an adrenergic neuronal blocking drug, 3) reserpine, an 
inhibitor of catecholamine vesicular storage and 4) phenoxybenz-
amine, an alpha receptor antagonist, were evaluated for their effects 




Preparation of Cultured Superior Cervical Ganglia of the Rat 
Superior cervical ganglia were excised from adult male Sprague-
Dawley rats (200-225 gm) and dissected free of their connective 
tissue sheathes aseptically. Ganglia were positioned at the gas-
liquid interface on stainless steel grids set in glass culture 
dishes that contained a chemically defined culture media prepared 
from BGJb medium (GIBCO) with the addition of modified lipids and 
salts as described by Silberstein et ale (1971). The media were 
supplemented with nerve growth factor (100 U/ml), penicillin (100 
U/ml) , streptomycin (100 ~g/ml) and ascorbic acid (100 mg/L). The 
chemical composition of the culture media is shown in Table 2. 
Ganglia were incubated in vitro at 37°C in an atmosphere of 95% 
°2/5% CO2 for 48 hours (Webb et al., 1975). 
Field Stimulation-Induced Release of 3H-Norepinephrine and 
3H-Propranolol 
To evaluate 3H-norepinephrine release, 48-hour cultured ganglia 
were incubated for 30 minutes in modified Krebs-Ringer-bicarbonate 
solution (Umbreit et al., 1972) supplemented with ascorbic acid (200 
mg/I) and glucose C2.0 g/l), adjusted to pH 7.4 and containing 0.1 
uM 3H-norepinephrine. All incubations were at 37°C in an atmosphere 
After 30 minutes, the tissue was removed and 
transferred to vials containing fresh incubating solution and washed 
for two 15 minute periods. The ganglia were then removed from the 
wash and suspended between two platinum electrodes. The electrodes 
were carefully lowered into a 13xlOO rom borosilicate tube which 
contained 1.0 ml of buffer and was sitting in a temperature 
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controlled water bath (37°C). After a two minute equilibrium period, 
the ganglia were transferred to another tube which contained 1.0 ml 
of fresh Krebs-Ringer-Bicarbonate solution for a period of 30 sec-
onds. This sample was assayed for tritium to determine the back-
ground or unstimulated efflux. The ganglia were again transferred 
to a fresh buffer solution and rectangular pulses of current (10 rnA, 
15-60 Hz and 4 msec) supplied by a Grass 844 stimulator and a Grass 
Stimulation Isolation Unit SIUS were passed through the electrodes 
for 30 seconds. The amperage was monitored by an oscilliscope. The 
tritium released in the baths was collected and quantitated by 
liquid scintillation spectrometry. Experiments using column chromo-
tography indicated that over 85% of the tritium released under these 
conditions was intact 3H-catecholamine. To determine the total 
3H-norepinephrine remaining in the tissue, the ganglia were blotted 
and homogenized in 500 ul of 0.4 N HelD 4 . The homogenates were 
centrifuged at 6500 rpm for 20 minutes. A 250 ul aliquot was taken 
and 750 ul of water was added as well as 10 ml of Triton X-IOO in 
toluene (1:2) which contained 0.55% 2,5-diphenyloxazole and 0.015% 
1,4-bis-2-(S-phenyloxzoylyl) benzene. 
To evaluate propranolol release, the ganglia were cultured for 
48 hours in the presence of O. 1 J-AM 3H-propranolol. Under these 
conditions, there was no evidence of propranolol metabolism or 
degradation. Moreover, this procedure does not interfere with the 
ability of the ganglia to develop axonal sprouts, to accumulate 
norepinephrine" or to release norepinephrine in response to field 
stimulation. Following 48 hours in culture, the ganglia were removed, 
washed for 30 minutes with fresh Krebs-Ringer-Bicarbonate solution 
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and stimulated as described for the study of 3H-norepinephrine 
release. To determine the total 3H-propranolol remaining in the 
tissue at the end of the stimulation protocol, the ganglia were 
blotted and homogenized in 500 ~l of 0.4 N HCl04 and 500 ~l acetoni-
trile. The homogenates were made basic with 500 ~l of 5.0 N NaOH 
and extracted with 6.0 ml of 1.5% isoamyl alcohol in toluene. A 4.0 
ml aliquot was assayed for radioactivity by liquid scintillation 
spectrometry. 
To evaluate the effect of altered concentrations of ions and 
pharmacological interventions on field stimulation-induced release 
of 3H-norepinephrine and 3H-propranolol, ganglia were cultured and 
incubated with 3H-norepinephrine and 3H-propranolol as previously 
described. The remainder of the experimental protocol was then 
conducted in buffer containing altered ion concentrations or the 
pharmacological test agents. 
To determine the effects of reserpine on the accumulation and 
field stimulation-i:nduced release of 3H-norepinephrine and 3H-pro-
pranolol, rats were administered subcutaneous injections of reserpine 
(5 .. 0 mg/kg) 24 and two hours before th~ ganglia were removed for 
culture .. Reserpine (1. 5 ~M) was also added to the culture media 
(Silberstein et al., 1972b). The ganglia were then washed and stim-
ulated in control buffer as previously described. 
3H-Propranolol or 3H-norepinephrine release from the field 
stimulated cultured superior cervical was expressed as a percentage 
>. 
of the total present prior to depolarization. In all cases, spon-
taneous or basal release was subtracted from total release observed 
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in the presence of depolarizing stimuli to obtain a value for net 
stimulation-induced release. 
Statistical Analysis 
Data are presented as means ± standard error of the mean. 
Means were compared by the use of Student's t-test for unpaired 
data. 
Drugs and Chemicals 
(1)-[4- 3 H]-Propranolol (sp. act. 22 Ci/mmol) and (dl)-[7- 3H]-
norepinephrine (sp. act. 11.8 Ci/mmol) were purchased from New 
England Nuclear Corp. Modified BGJb culture medium was obtained from 
Grand Island Biological Company and nerve growth factor from Burroughs 
Wellcome and Company. Additional drugs used were bretylium tosylate 
(Arnar Stone), reserpine (Ciba Geigy) and phenoxybenzamine hydro-
chloride (Smith Kline and French). 
RESULTS 
3H-Norepinephrine Uptake by Cultured Ganglia 
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Freshly excised superior cervical ganglia accumulated 3H-nor-
epinephrine from incubating media that contained labelled cate-
cholamine. Ganglia placed in organ culture for varying time inter-
vals exhibited a time-dependent increase in 3H-norepinephrine uptake 
over the 48-hour culture period studied (Figure 1). A significant 
increase in neurotransmitter uptake was observed after only six 
hours in culture. After 48 hours, 3H-norepinephrine uptake was 
enhanced approximately eight-fold as compared to freshly excised 
ganglia, a finding consistent with that reported by Silberstein et 
ala (1972b) who concluded that the increased uptake of norepine-
phrine by the cultured ganglia was a result of the growth of axonal 
sprouts from the cell bodies of the sympathetic neurons. 
Field Stimulation-Induced Release of 3H-Norepinephrine and 3H-Pro-
pranolol 
Field stimulation of 48-hour cultured superior cervical ganglia 
pre loaded with 3H-norepinephrine or 3H-propranolol resulted in the 
release of both molecules into the incubation bath in a frequency-
dependent manner (Figure 2). When ganglia were stimulated with 15 
rnA of current of 4 msec duration for one minute, a frequency of 60 
Hz evoked the release of approximately 41% of the accumulated 3H-
norepinephrine and 2.4% of the 3H-propranolol taken up. At a fre-
quency of 15 ~Hz, 6.4% of the norepinephrine and 0.4% of the total 
propranolol were released. The· time course of release of both 
molecules at 15 Hz is shown in Figure 3. The release of propranolol 
was essentially linear for 60 seconds under these conditions. The 
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stimulus parameters of 10 rnA, 15 Hz and 4 msec for 30 seconds were 
taken as the minimal conditions for obtaining a reproducible release 
of propranolol of sufficient magnitude that reductions in release 
could be detected and were employed for the remainder of the study. 
Influence of Ions and Drugs on 3H-Norepinephrine and 3H-Propranolol 
Release 
Release of neurotransmitter by exocytosis is dependent on the 
extracellular concentration of calcium and magnesium ions (Rubin, 
1970). The influence of these ions on the stimulation-induced 
release of norepinephrine and propranolol from 48-hour cultured 
ganglia is shown in Figure 4. Removal of extracellular calcium and 
elevation of magnesium (12 mM) significantly decreased the field 
stimulation-induced release of norepinephrine. Under control con-
ditions ++ ([Ca ] = 2.5 mM), stimulation evoked the release of 2.6 ± 
o 
0.4% of the norepinephrine taken up by the ganglia whereas only 1.0 
± 0.3% of the total neurotransmitter was released by stimulation 
under calcium-free conditions, a reduction of 60%. In comparison, 
removal of calcium and elevation of magnesium had no effect on the 
stimulation-induced release of propranolol (Figure 4). Bretyliwn, 
an adrenergic neuronal blocking drug that inhibits the secretion of 
norepinephrine from sympathetic neurons, also reduced norepinephrine 
release from the field stimulated cultured ganglia (Figure 5). 
Bretylium, at a concentration of 100 J-lM,. decreased neurotransmitter 
overflow by 50%. Phenoxybenzamine (10 J.lM), an alpha receptor blocker 
which antagonizes the negative feedback modulation of exocytosis 
(Langer, 1977), enhanced the stimulation-induced release of nor-
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epinephrine from the cultured ganglia by 64% (Figure 6). However, 
neither bretylium nor phenoxybenzamine altered the stimulation-
induced release of propranolol from the ganglia (Figures 5 and 6). 
Reserpine inhibits the carrier-mediated transport of biogenic 
amines into synaptic storage vesicles and pretreatment with reserpine 
almost abolished the accumulation of norepinephrine by 48-hour 
cultured ganglia (Figure 7). Norepinephrine accumulation averaged 
6.5 ± 0.7 pmal/ganglion in ganglia cultured from untreated animals 
as compared to 0.14 ± 0.01 pmal/ganglion in ganglia cultured from 
treated animals. Field stimulation of ganglia from untreated animals 
promoted the release of 138 ± 43 fmol norepinephrine/ ganglion, a 
value tha t represented 2. 1% of the total 3H-norepinephrine accumu-
lated. A small but measurable release of 3H-norepinephrine was also 
observed in ganglia from reserpinized animals. Although norepi-
nephrine release was reduced to 7.5 ± 2.6 fmol/ganglion, this amount 
represented approximately 5.4% of the total 3H-norepinephrine 
accumulated by the ganglia from the pretreated animals (Figure 8). 
In comparison, propranolol accumulation was 8.8 ± 0.5 pmol/ganglion 
in controls and was not altered by pretreatment with reserpine 
(Figure 7). Moreover, propranolol release in response to field 
stimulation of the cultured ganglia was also unchanged by reserpine 
pretreatment (Figure 8). 
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DISCUSSION 
Superior cervical ganglia removed from rats and placed in organ 
culture exhibited an increased uptake of norepinephrine with time in 
culture. After 48 hours in culture, norepinephrine accumulation by 
the ganglia was eight-fold greater than that found in freshly removed 
tissue. This observation is comparable to the findings of Silberstein 
et al. (1972b) who related the enhanced accumulation of amine to the 
growth of axonal sprouts from the cell bodies of the sympathetic 
neurons. Norepinephrine accumulation in the cultured ganglia was 
sens i ti ve to pretreatment wi th reserpine. Moreover, the norepin-
ephrine taken up was released in response to electrical field stimu-
lation. Transmitter release was calcium-dependent, inhibited by 
bretylium and enhanced by phenoxybenzamine. These observations are 
consistent with previous reports (Kopin et a1., 1973) and indicate 
that sympathetic ganglia, after 48 hours in culture, possess the 
principal neurotransmitter mechanisms of sympathetic nerve terminals 
and present a useful in vitro model for studying neural release 
processes. 
Stimulation of the 48-hour cultured ganglia preloaded with 
3H-norepinephrine released in 30 seconds 2.6 ± 0.4% of· the total 
3H-norepinephrine taken up. Bretylium decreased norepinephrine 
release by 50% while phenpxybenzamine was observed to produce a 64% 
enhancement of neurotransmitter overflow. The magni tude of the 
field stimulation-induced 3H-norepinephrine release observed, as 
well as the degree of bretylium-induced inhibition and the phenoxy-
benzarnine-induced enhancement of release found, are in close agree-
ment with the findings of Vogel et a1. (1972) in their study of 
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neurotransmitter release from cultured sympathetic ganglia. Vogel 
and coworkers, however, reported that removal of calcium and addition 
of EGTA (1.0 mM) to the incubation bath reduced the stimulation-
induced release of 3H-norepinephrine from cultured ganglia by 93%, 
while in the present study, removal of extracellular calcium and 
addition of magnesium (12 mM) inhibited 3H-norepinephrine release by 
only 60%. It is probable that EGTA, a calcium chelator, is more 
efficient at removing free and bound extracellular calcium than is 
the combination of reduced calcium and elevated magnesium. 
The action of reserpine to inhibit the accumulation of 3H-nor-
epinephrine by cultured ganglia is consistent with the effects of 
reserpine to inhibit the storage of norepinephrine by noradrenergic 
nerve terminals in vivo. Although reserpine pretreatment decreased 
3H-norepinephrine accumulation in the cultured ganglia by 98%, a 
small amount of tritium was nonetheless retained. In addition, 
field stimulation consistently promoted the release of radioactivity 
from the reserpine pretreated ganglia. The release observed was 
small and equivalent to only 7.5 fmol/ganglion and may have con-
sisted of metabolites of 3H-norepinephrine present within neurons 
but outside the synaptic storage vesicles. However, release of 
intact neurotransmitter, accumulated despite the presence of reser-
pine, would be consistent with the fact that reserpine does not have 
..r, 
a direct action to alter exocytosis. 
Superior cervical ganglia of the rat when cultured for 48 hours 
"> 
and then acutely incubated with 3H-propranolol (0.1 ~M) accumulated 
the drug slowly and tissue levels reached 9.0 pmol/mg tissue after 
60 minutes (Saelens et al., 1977) . In the present experiments, 
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ganglia cultured for 48 hours in the presence of 0.1 IJM 3H-pro-
pranolol accumulated 9.0 pmal/ganglion, an amount similar to that 
reported by Saelens et ale 
pmol/ganglion observed for 
(1977) and slightly greater than the 6.5 
3H-norepinephrine uptake. Reserpine 
treatment, in contrast to its effect on norepinephrine, failed to 
alter the uptake and retention of propranolol by the ganglia. This 
result suggests either that propranolol does not enter the storage 
vesicle or, more likely, that penetration of propranolol into the 
storage vesicle is independent of the reserpine-sensitive carrier 
mediated system which exists for the transport of biogenic amines. 
Some degree of propranolol accumulation into the storage vesicle 
would be predicted in view of the lipophilic nature of the propranolol 
molecule and the acidic internal environment reported for storage 
vesicles (Henry and Wyllie, 1981). 
Field stimulation released both propranolol and norepinephrine 
from 48-hour cultured ganglia in a frequency-dependent manner. 
Although the accumulation of propranolol and norepinephrine in this 
preparation was quantitatively similar, the fractional release of 
propranolol produced by field stimulation was low compared to the 
release of norepinephrine (0. 15% vs 3.00%). This observation may 
reflect a more generalized distribution of propranolol throughout 
the nerve cell while norepinephrine is almost entirely localized 
within the synaptic storage vesicles from which it is released in 
response to the depolarizing stimulus. Moreover, the release mecha-
nism for prop'ranolol in cultured ganglia appears to be clearly 
distinct from that for norepinephrine. Norepinephrine release was 
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predictably diminished by low extracellular calcium, reserpine 
treatment and bretylium and enhanced in the presence of phenoxy-
benzamine. None of these manipulations altered the stimulation-
induced release of propranolol. Collectively, the data support the 
concept that propranolol release under the conditions of these 
experiments occurs principally by some type of nonexocytotic process. 
In addition, the observations that reserpine treatment effectively 
abolished norepinephrine accumulation without influencing the accumu-
lation or release of propranolol demonstrate that norepinephrine 
release is not a requirement for the stimulation-induced release of 
propranolol from adrenergic tissue. 
Calcium-independent, presumably nonexocytotic, release processes 
have also been described previously for several endogenous substances 
including 
(Haycock, 
taurine (Sieghart and Heckl, 1976), y-aminobutyric acid 
et al., 1978) and acetylcholine (Tauc, 1982; Meyer and 
Cooper, 1983). Propranolol may be released from either the cell 
cytoplasm or membrane by a nonexocytotic mechanism shared by one or 
more of the endogenous molecules. Nonexocytotic release processes, 
however, are not well understood. Conceivably, the cationic form of 
propranolol (99% ionized at physiological pH) may distribute accord-
ing to the potential field that exists across cell membranes such 
that membrane hyperpolarization would allow propranolol accumulation 
and membrane depolarization would promote propranolol efflux from 
the cell. In this way, propranolol may be acting similarly to the 
lipophilic cationic dyes used in estimating membrane potential 
(Waggoner, 1979). Alternatively, the propranolol release may occur 
from membranes in response to perturbations associated wi th the 
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depolarizing event. Propranolol has been reported to bind to nega-
tively charged phospholipids in natural and artificial membranes 
(Dachary-Prigent et a1., 1979; Liillman and Wehling, 1979; Surewicz 
and Leyko, 1981). These interactions are believed to depend in part 
upon electrostatic attractions and may be influenced by changes in 
the potential field across the membrane. Membrane depolarization, 
in addition to inducing changes in electrostatic interactions of 
membrane constituents, may also promote changes in phospholipid 
turnover. Increased hydrolys is of phosphatidylinosi tol has been 
reported in guinea pig synaptosomes during depolarization (Pickard 
and Hawthorne, 1978). If negatively charged phospholipids serve as 
binding sites for propranolol, an increased turnover of these phos-
pholipids could result in an increased efflux of drug from the cell. 
The release of propranolol from cultured ganglia in response to 
electrical stimulation supports the hypothesis that nerve stimulation 
promotes the release of the beta receptor blocking drugs from pre-
synaptic adrenergic neural tissue 
ments in the dog heart (Daniell 
hindlimb (Russell et al., 1983). 
as suggested by in situ experi-
et al., 1979) and the perfused 
However, further extrapolation of 
these results to the nerve terminal is complicated by the fact that 
while norepinephrine is clearly localized to storage vesicles of 
newly developed axonal sprouts (Silberstein et al., 1972b) in cultured 
ganglia, the distribution of propranolol within the ganglion is 
unknown. It is likely that propranolol readily distributes within 
cell bodies as well as nerve terminals and it is conceivable that 
the propranolol release observed may occur principally from cell 
bodies which could obscure the characteristics of release from the 
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nerve ending-like axonal sprouts. In fact, data on the accumulation 
and release of propranolol from synaptosomes (Chapter III) indicate 
important differences between the cultured ganglion and synaptosome 
preparations. 
The results of the present study have demonstrated 1) that 
propranolol may be released by electrical stimulation from neurons 
in the absence of effector tissue, 2) that stimulation-induced 
release of propranolol from cultured ganglia occurs by a different 
mechanism than that for norepinephrine and appears to be the result 
of a nonexocytotic process, and 3) that norepinephrine release does 
not seem to be a requirement for the stimulation-induced release of 
propranolol to occur. 
CHAPTER III 
DEPOLARIZATION-INDUCED RELEASE OF PROPRANOLOL AND ATENOLOL 
FROM RAT CORTICAL SYNAPTOSOMES 
INTRODUCTION 
It has been demonstrated previously that propranolol is 
released along with norepinephrine during sympathetic nerve stimu-
lation at several sites. In the heart, activation of the cardiac 
accelerator nerves or intravenous administration of tyramine evoked 
a parallel increase in the overflow of both propranolol and norepine-
phrine into the coronary sinus blood of chronically pretreated dogs 
(Daniell et al., 1979). Nerve stimulation-induced release of pro-
pranolol was also observed in the spleen and the vasculature of the 
peripheral canine hindlimb (Russell et al., 1983). Similarly, in 
man, treadmill exercise was found to produce a simultaneous elevation 
of propranolol and norepinephrine in the plasma of hypertensive 
patients and normal volunteers receiving therapeutic doses of drug 
(Hurwitz et al., 1983). Thus, propranolol release in association 
with sympathetic nerve stimulation appears to represent a generalized 
phenomenon at adrenergic neuroeffector junctions. 
Propranolol release by field stimulation has also been observed 
using cultured superior cervical ganglia of the rat as an in vitro 
model neural system (Chapter II). Propranolol release in these 
experiments appeared to occur by a mechanism different from that 
found for norepinephrine in that propranolol release was not calcium-
dependent nor was it influenced by reserpine, bretylium or phenoxy-
benzamine. These observations raised the possibility that propranolol 
release from the ganglia might occur from cell bodies which constitute 
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the bulk of the preparation and that such release could obscure the 
characteristics of any release occuring from the nerve terminal-like 
axonal sprouts. In an attempt to better examine the release of 
propranolol from nerve terminals, experiments were designed utilizing 
brain synaptosomes prepared from rat cerebral cortex. 
Synaptosomes, originally referred to as isolated nerve endings, 
are nerve terminals that are sheared from their axons during the 
process of homogenization of brain tissue and then reseal. Centrif-
ugation of this tissue homogenate on a discontinuous sucrose gradient 
allows for the relative separation of nerve terminals from other 
neural components and cellular constituents such as myelin and 
mitochondria. Morphological studies conducted by DeRobertis (1962) 
and Gray and Whittaker (1964) showed that synaptosomes prepared by 
this procedure have a diameter of 0.7 - 1.0 microns and reseal to 
enclose mitochondria, synaptic vesicles and cytoplasmic enzymes, 
including acetylcholinesterase and lactate dehydrogenase. Fragments 
of postsynaptic membrane also may adhere to the synaptosomal plasma 
membrane (Figure 9). The synaptosomal preparation contains a hetero-
genous population of nerve terminals. Autoradiographic studies of 
synaptosomes prepared from the cerebral cortex of rat suggest that 
5% of the terminals accumulate 3H-norepinephrine, 30% of the termi-
nals accumulate gamma-aminobutyric acid (Iversen and Schon, 1972), 
and approximately 10-20% of the nerve terminals are reported to be 
cholinergic (Bradford, 1975). In the past twenty years, attempts 
have been made to increase the yield of synaptosomes, to decrease 
the preparative time and to isolate more homogeneous populations of 
nerve terminals; however, these efforts to improve the purity, 
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viability or homogeneity have not been entirely successful and many 
investigators continue to use the preparation that was described by 
Gray and Whittaker in 1964. Bradford (1975) assessed the viability 
of this preparation and found that it retained biochemical integrity 
as determined by respiratory rate, ion and amino acid content for up 
to three hours under standard experimental conditions. 
Synaptosomes retain many functional properties associated with 
intact cells (DeLores Arnaiz and DeRobertis, 1972; Bradford, 1975). 
Synaptosomes possess ion transport processes for sodium (Ling and 
Abdel-Latif, 1968) and potassium (Blaustein and Goldring, 1975), a 
membrane potential that approximates the potassium diffusion poten-
tial (Blaustein and Goldring, 1975) and active transport systems for 
biogenic amines (Boganski et a1., 1968), choline (Marchbanks, 1968; 
Haga, 1971) and y-aminobutyric acid (Varon et a1., 1965). Moreover, 
in response to depolarizing stimuli, synaptosomes demonstrate a 
change in membrane potential that can be monitored by potential-sen-
sitive fluorescent probes (Blaustein and Goldring, 1975), an increase 
in calcium uptake (Blaustein et a1., 1972; Blaustein, 1975; Ferren-
delli and McQueen, 1982) and an increase in the release of norepine-
phrine (Blaustein et al., 1972; Blaustein, 1975; Raiteri and Levi, 
1978) and other neurotransmitters (DeBelleroche and Bradford, 1972; 
Bradford, 1975; Cotman et al., 1976; Mulder and Snyder, 1976) . 
The objectives of the present studies were to determine if 
propranolol could be released from rat cortical synaptosomes in 
response to depolarizing stimuli such as potassium and veratridine, 
and, if so, to determine whether the stimulus-induced release of 
propranolol was indeed the result of membrane depolarization. 
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Experiments were designed to characterize the mechanism of propranolol 
release as it compared to that of norepinephrine, used as an index 
of exocytosis. In addition, propranolol release was compared to the 
release of the more polar, cardioselective beta receptor blocking 
drug atenolol (for structural formulas see Figure 10). 
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METHODS 
Preparation of Synaptosomes 
Synaptosomes were prepared from rat cerebral cortex by discon-
tinuous sucrose density gradient centrifugation as described by Gray 
and Whittaker (1962) (Figure 11). All preparative procedures were 
performed at 4°C and each sucrose solution contained 5.0 mM N-2-
hydroxyethylpiperazine-N'-2-ethanesulfonic acid (REPES) and was 
adjusted to pH 7.4 (Fleming et al., 1980). Adult male Sprague 
Dawley rats (225-275 g) were killed by decapitation and whole brains 
were removed. The cerebral cortex was dissected free and homoge-
nized in 10 volumes of ice cold 0.32 M sucrose using a glass homoge-
nizer with a loosely fitting Teflon pestle (0.25 rom clearance) at 
800 rpm for 10 passes. The resulting homogenate was centrifuged at 
1000 x g for 10 minutes and the supernatant was decanted and retained. 
The pellet was resuspended with 0.32 M sucrose and centrifuged at 
1000 x g for an additional 10 minutes. The resulting supernatant 
was added to that from the first centrifugation and centrifuged at 
17,000 x g for 20 minutes to yield the crude mitochondrial pellet or 
P
2 
fraction. The P2 fraction was resuspended in 0.32 M sucrose (6.0 
ml/gradient), layered over a discontinuous sucrose density gradient 
consisting of equal volumes (16 ml) of 1.2 M and 0.8 M sucrose 
solutions, and then centrifuged using a Beckman SW-27 rotor at 
53,000 x g for 120 minutes. The synaptosome-enriched fraction was 
collected from the 0.8/1.2 M sucrose interface, diluted wi th an 
equal volume of water and centrifuged at 27,000 x g for 15 minutes 
to yield the synaptosomal pellet. The synaptosomal pellet was 
resuspended in a volume of 0.32 M sucrose equivalent to 2.0 ml/gm 
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wet tissue weight and was then diluted with cold oxygenated modified 
Krebs-Ringer buffer (pH 7.4) of the following composition: NaCl, 
145 mM; KCI, 5.0 mM; CaC1 2 , 2.0 mM; MgS04 , 1.2 mM; Na 2HP04 , 1.2 mM; 
glucose, 10 mM; HEPES, 20 roM to a final volume equivalent to 5.7 
ml/gm wet tissue weight. The addition of sucrose to the buffer in 
this resuspension procedure has been reported to further stabilize 
synaptosomes (Sperk and Baldessarini, 1977). Protein concentration 
was determined using the method of Lowry et a1. (1951). 
Release of 3H-Norepinephrine, 3H-Propranolol and 3H-Atenolol from 
Rat Cortical Synaptosomes. 
To load the synaptosomes with 3H-norepinephrine, an aliquot of 
the synaptosome-enriched preparation was mixed with warmed (30°C) 
oxygenated buffer and incubated at 30°C for five minutes to allow 
for equilibration of the preparation (Blaustein and Goldring, 1975). 
Synaptosomes were then incubated at 30°C for 10 minutes in the 
presence of 0.1 ~M 3H-norepinephrine. Extracellular 3H-norepi-
nephrine was removed by centrifuging the labelled synaptosomes at 
12,000 x g for five minutes and the pellet was resuspended in cold 
oxygenated buffer. Aliquots of the labelled synaptosomes (0.35 ml 
which represented approximately 100-150 ~g protein) were then pipetted 
into 12 x 75 mm borosilicate tubes on ice. For the norepinephrine 
experiments 12.5 JJM nialamide, a monoamine oxidase inhibitor, was 
included in the incubation buffer. After warming each sample at 30°C 
for five minutes, the samples were diluted with either control 
buffer or test buffer containing elevated potassium concentrations 
or veratridine. In experiments in which the concentration of extra-
cellular potassium was increased, the concentration of sodium was 
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decreased to maintain isosmotic conditions. Some samples were 
diluted and filtered immediately to determine the amount of 3H-drug 
associated with the synaptosomes at "zero" time. At the end of the 
releasing period, the synaptosomes were collected by vacuum fil-
tration on glass fiber filters (Whatman GF-B) and rinsed twice with 
5.0 ml of ice-cold buffer. The amount of 3H-drug nonspecifically 
associated with the filters was determined by filtration of an 
aliquot of buffer containing 3H-drug in the absence of synaptosomal 
protein and generally represented 10% or less of the radioactivity 
associated with the filters in the presence of protein. The filters 
were removed from the Millipore filter apparatus, placed in glass 
scintillation vials and 10 ml of a toluene based scintillation 
cocktail was added (150 mIlL SAS solubilizer for aqueous samples 
(RPI), 4.0 gIL 2,5-diphenyl-oxazole and 50 mg/L 1,4-di-(2-(S-phenyl-
oxazolyl))benzene). The radioactivity associated with the filters 
was quantitated by liquid scintillation spectrometry. Drug or 
transmitter release from synaptosomes was generally expressed as a 
percentage of the total present prior to depolarization. In all 
cases, spontaneous or basal release was subtracted from total release 
observed in the presence of depolarizing stimuli in order to arrive 
at a value for net stimulus-induced release. Under conditions 
similar to those employed here, 90% of the norepinephrine taken up 
by the synaptosomes was retained in the form of the parent compound 
(Horn, 1973; Marquardt et al., 1978). 
To examine propranolol and atenolol release, synaptosomes were 
incubated at 30°C with 0.1 uM 3H-propranolol for 10 minutes or 1.0 
~M atenolol for 20 minutes essentially as described above for 
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norepinephrine. This concentration of atenolol as well as an 
increased incubation time was utilized to achieve higher steady-state 
concentration of atenolol. In addition, for atenolol experiments, 
twice as much protein was used per filter and each filter was washed 
three times with 5.0 ml of ice-cold buffer, conditions that maximized 
synaptosomal-associated drug and reduced nonspecific binding to 
filters. Preliminary experiments investigating the spontaneous and 
potassium-induced release of 3H-propranolol from prelabelled rat 
cortical synaptosomes demonstrated that 69% of the synaptosome-associ-
ated propranolol was released spontaneously in five minutes and this 
release was reduced to 3% by the presence of extracellular drug 
(0.095 IJM). Therefore, in subsequent experiments the spontaneous 
efflux of propranolol and atenolol was limited by maintaining extra-
synaptosomal 3H-drug throughout the experiment at a concentration of 
0.08 IJM 3H-propranolol or 0.8 IJM 3H-atenolol. Under these conditions, 
approximately 5% of the drug associated with the synaptosome was 
lost spontaneously over the time course of an experiment, typically 
two to three minutes. Samples were incubated at 30°C for five 
minutes and then diluted with either control buffer or test buffer 
containing elevated potassium concentrations or veratridine. The 
reaction was terminated by the vacuum filtration method previously 
described for the norepinephrine release experiments. In all exper-
iments in which the concentration of potassium or other monovalent 
cations was elevated, the sodium concentration was reduced to main-
tain isomotic conditions. Removal of sodium and replacement with 
another relatively impermeable ion such as choline had no effect on 
propranolol or atenolol release. 
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In experiments to evaluate the effects of ions and drugs on 
norepinephrine, propranolol and atenolol release, the ions and drugs 
were added to the prelabelled synaptosomes and incubated for five 
minutes prior to the addition of the depolarizing stimuli and were 
also present in the depolarizing media. In initial experiments, the 
relationship between the concentration of drug and its effect on 
norepinephrine release was determined. A concentration of drug 
which significantly affected norepinephrine release was evaluated 
for its effect on propranolol and atenolol release. Propranolol and 
atenolol were not metabolized by synaptosomes in vitro. 
Determination of Changes in Synaptosomal Membrane Potential 
Synaptosomal membrane potential was monitored by measuring the 
fluorescence of the voltage-sensitive dye, 3,3'-dipropyl-2,2'-thio-
dicarbocyanine, designated as diS-C -(5) 
3 
(Sims et a1., 1974). 
Fluorescence was measured with an Aminco-Bowman spectrophotofluor-
ometer attached to a strip chart recorder. Excitation and emission 
wavelengths were 622 nm and 670 run, respectively, and 1.0 IDOl slit 
widths were used. Fluorescence measurements were made after addition 
of diS-C
3
-(S) to a suspension of synaptosomes in Krebs-Ringer buffer 
containing varying concentrations of potassium or other alkali metal 
ions. As before, osmolarity was maintained constant by adjustments 
in the concentration of sodium. Specifically, an aliquot of synap-
tosome suspension (20 ~g protein) was added to prewarmed incubation 
medium (30 0 C) to give a final volume of 1.5 mi. The cuvette was 
placed in the spectrophotofluorometer and allowed to equilibrate for 
one minute. Dye solution was then added to give a concentration of 
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1.0 ~M and fluorescence was recorded. Depolarizaton of the synapto-
somes was reflected as an increase in the intensity of dye fluore-
scence. The potassium-induced increase in fluorescence intensity 
was not greatly influenced by the presence of the potassium ionophore, 
valinomycin (0.3 ~M) (Figure 12), a finding is consistent with the 
proposal that the synaptosomal membrane potential approximates the 
potassium diffusion potential (Blaustein and Goldring, 1975). The 
fluorescence observed was expressed arbitrarily as percentage of 
that observed when the external potassium concentration was 100 mM. 
To determine if the relative changes in dye fluorescence induced 
by different alkali metal ions resulted from their ability to depolar-
ize membranes, the fluorescence of solutions containing dye and each 
of the alkali metal ions in the absence of protein was examined to 
control for possible dye-ion interactions. 
Treatment with 6-Hydroxydopamine. 
To determine the effect of 6-hydroxydopamine on the accumulation 
and release of propranolol and atenolol required that the animals be 
pretreated with the drug. The method of Uretsky and Iversen (1970) 
was followed. Two doses of 250 ~g were injected at 24 hour intervals 
into the cerebrospinal fluid of the lateral ventricle of the rat 
brain (Noble et al., 1967). The animals were killed 20-21 days 
after the last injection and synaptosomes were prepared as previously 
described. To assess the degree of adrenergic nerve terminal destruc-
tion in the cerebral cortex of 6-hydroxydopamine treated animals, 
endogenous norepinephrine content was determined using the radio-
enzymatic method of Henry et ale (1975). 
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Statistical analysis 
Data are presented as means ± standard error of the mean. 
Where appropriate, means were compared by the use of Student t s 
t-test for paired or unpaired data. The remainder of the results 
were analyzed by repeated measures analysis of variance, followed by 
least significant difference analysis. 
Drugs 
(1)-[4- 3H]-Propranolol (sp. act. 22 Ci/mmol) and (dl)-[7- 3H]-nor-
epinephrine (sp. act. 11.8 Ci/mmol.) were purchased from New England 
Nuclear Corp. (dl)-[2- 3 H]-Ateno!ol (sp. act. 31 Ci/mmol.) was a gift 
from leI Pharmaceuticals, Macclesfield, England. Veratridine was 
obtained from Sigma and tetrodotoxin and the calcium ionophore, 
A23187, from Calbiochem. 
RESULTS 
3H-Proprano!ol and 3H-Atenolol Accumulation 
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Experiments to determine the time courses for synaptosomal 
accumulation of 3H-propranolol (0.1 ~M) and 3H-atenolol (0.1 ~M) at 
30°C were conducted by Street and coworkers (1984; unpublished 
observations). Accumulation of propranolol was rapid with 75% of 
maximal uptake achieved within seconds after addition of labelled 
drug to the synaptosomal suspension (Figure 13). Equilibrium was 
attained by one minute, at which time 20.0 ± 1.5 pmoles propranolol 
were accumulated per mg synaptosomal protein. In comparison, atenolol 
was accumulated at a slower rate, reaching a steady state concentra-
tion of 0.6 ± 0.1 pmoles/mg protein after 15 minutes of incubation. 
On the basis of an intrasynaptosomal water space of 4.0 - 6.2 ~l/mg 
protein (Blaustein and Goldring, 1975; Deutsch and Rafalowska, 1979; 
Wood and Wyllie, 1983), the equilibrium distribution of propranolol 
between tissue and incubation medium was estimated to represent a 33 
to 50-fold synaptosomal concentration of drug. The corresponding 
distribution ratio for atenolol, however, was in the range of 1.0 to 
1.4. 
3H-Propranolol Release 
Exposure of synaptosomes preloaded with [3H] -propranolol to 
elevated concentrations of external potassium produced a concen-
tration-dependent increase in drug efflux (Figure 14). At 75 roM 
external potassium, approximately 26% (5.1 ± 0.9 pmoles/mg protein) 
of the total propranolol accumulated by the synaptosomes was released. 
The potassium-induced release of propranolol was rapid and was 
complete within 15-30 seconds for all concentrations of ion examined. 
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Spontaneous efflux of drug over the three minute time course of these 
experiments was 5.0 ± 1.1% of the tissue total. For comparison, the 
time course of potassium-induced [3H] -norepinephrine release from 
synaptosomes is illustrated in Figure 15. At all concentrations of 
external potassium, norepinephrine release was continuous for the 
three minutes examined and appeared to be linear between the one and 
three minute time points. After three minutes exposure to 75 mM 
potassium, approximately 15% (1.1 ± 0.2 pmol/mg protein) of the 
norepinephrine taken up by the synaptosomes was released. 
To determine if the release of propranolol in response to 
elevated potassium was related to membrane depolarization, the 
ability of a series of alkali metal ions to promote propranolol 
release was examined and compared with the relative actions of these 
ions to depolarize synaptosomal plasma membranes. Rubidium was equi-
potent to potassium in producing propranolol release (Figure 16). 
Cesium, however, was less potent to the extent that a three-fold 
greater concentration of cesium was required to elicit release 
equivalent to that observed with potassium or rubidium. The concen-
tration of ion required to release in one minute 15% of the pro-
pranolol accumulated by the synaptosomes was 21 ± 3 mM for potassium, 
20 ± 2 roM for rubidium and 61 ± 4 mM for cesium (p < 0.01, when 
compared to potassium). For these three ions, propranolol release 
was linearly related to the log of the external ion concentration 
over the range examined. Lithium ion, in concentrations up to 75 
roM, had no effect on propranolol efflux. 
The effect of these ions to induce changes in the synaptosomal 
membrane potential was monitored with the voltage-sensitive fluores-
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Depolarization of the cent dye, 
reflected as an increase in the intensity of 
synaptosomes was 
dye fluorescence 
(Figure 16). The potassium-induced increase in fluorescence 
intensity was not greatly influenced by the presence of the 
potassium ionophore, valinomycin (0.3 ~M). This finding as well as 
the finding that a linear relationship was observed between the log 
of the external potassium concentration and synaptosomal fluorescence 
(Figure 16) are consistent with the proposal that synaptosomal 
membrane potential approximates the potassium diffusion potential 
(Blaustein & Goldring, 1975). Rubidium ion was essentially equipotent 
to potassium in producing membrane depolarization, whereas cesium 
was approximately three times less potent and lithium had no effect 
on membrane potential. As shown in Figure 17, the action of these 
ions to depolarize synaptosomes was highly correlated (p < 0.01; r = 
0.96) with their ability to promote propranolol release. 
To determine if changes in intrasynaptosomal pH were influencing 
the potassium-induced release of propranolol, the effect of the 
proton ionophore, carbonyl-cyanide-m-chlorophenylhydrazone (CCCP), 
on potassium-induced propranolol release was determined. The presence 
of CCCP during potassium-induced depolarization would allow the 
equilibration of protons across membranes and thus prevent proton 
gradients from establishing during depolarization. CCCP, when 
present during the one minute release period at a concentration of 
1.0 ~M, increased the potassium-induced release of propranolol from 
21.8 ± 2.3% to 37.0 ± 3.2% (Figure 18). 
spontaneous efflux of propranolol. 
CCCP had no effect on the 
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Exposure of [3H]-propranolol-loaded synaptosomes to the membrane 
depolarizing agent veratridine also resulted in an increase in drug 
efflux (Figure 19). At a concentration of 10 ~M, veratridine released 
over 30% of the propranolol accumulated by the synaptosomes. Maximal 
release was attained within one minute. The prior addition of 
tetrodotoxin (1.0 ~M), in a concentration which almost totally 
inhibited veratridine-induced release of norepinephrine (Figure 19), 
reduced the veratridine-induced release of propranolol by 40% but 
did not abolish the effect. 
had no greater effect. 
3H-Atenolol Release 
Higher concentrations of tetrodotoxin 
The influence of increasing concentrations of potassium on 
[3H]-atenolol release is shown in Figure 20. Elevation of external 
potassium resulted in a concentration-dependent increase in atenolol 
efflux from the synaptosomes. Exposure to 75 mM potassium for two 
minutes released approximately 25% (2.5 ± 0.3 pmol/mg protein) of 
the total atenolol accumulated. The time course of atenolol release 
was slower than that found for propranolol (Figure 14) and, for all 
concentrations of potassium, was approximately linear after the 
ini tial 30 second time point. In this regard, potassium-induced 
atenolol release closely resembled the release observed for norepi-
nephrine (Figure 15). Spontaneous atenolol efflux averaged 4.9 ± 
0.7% over two minutes. Addition of external cesium was also 
observed to release atenolol from synaptosomes with 75 mM cesium 
releasing in two minutes 12.3 ± 1.1% of the atenolol accumulated. 
This release was approximately equal to that produced by 25 mM 
potassium (15.6 ± 2.0%). 
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The addition of veratridine to atenolol-loaded synaptosomes 
also produced an increase in drug efflux. Exposure to 10 ~M vera-
tridine for two minutes released approximately 15% (1.0 ± 0.1 pmol/ 
mg protein) of the total atenolol accumulated. Atenolol release did 
not reach a plateau over the time period examined. Tetrodotoxin 
(1.0 tJM) inhibited the veratridine-induced release of atenolol by 
90% (Figure 21), in contrast to its partial antagonism of veratri-
dine-induced propranolol release (Figure 19). 
The effect of the proton ionophore, CCCP, on potassium-induced 
release of atenolol is shown in Figure 18. CCCP, present during the 
two minute release period at a concentration of 1. 0 ~M, had no 
effect on the spontaneous efflux of atenolol and did not signifi-
cantly influence the potassium-induced release of atenolol. 
Calcium Dependence of Drug Release 
To evaluate the importance of extracellular calcium in these 
release processes, potassium-induced release of [3H] -propranolol, 
[3H]-atenolol and [3H]-norepinephrine was examined in the presence 
and absence of the calcium ion. The potassium-induced release of 
all three compounds was sensitive to extracellular calcium, though 
to varying degrees. In calcium-free medium supplemented with 2.0 roM 
ethylene glycol bis(B-aminoethyl ether)-N,N'-tetraacetic acid (EGTA), 
potassium-induced release of propranolol was reduced by 37% while 
atenolol release was decreased 68% and norepinephrine release 82% 
(Table 3). 
The effects of the calcium ionophore, A23187, to release 3H-nor-
epinephrine, 3H-propranolol and 3H-atenolol were also determined in 
the presence and absence of extracellular calcium. Norepinephrine 
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release induced by A23187 was linear and continuous for the five 
minute period examined (Figure 22). A five minute exposure to 1.0 
IJM A23187 in the presence of calcium released 23.6 ± 0.2% of the 
norepinephrine taken up by the synaptosomes. Removal of extracell-
ular calcium and addi tion of EGTA (2.0 roM) reduced the ionophore-
induced release of norepinephrine at five minutes to 12.8 ± 0.9%, a 
value that represented an inhibition of 46%. The time course of the 
ionophore-induced release of propranolol is shown in Figure 23. In 
the presence of calcium, A23187 (1.0 IJM) released in three minutes 
approximately 61.1 ± 0.6% of the total propranolol accumulated by 
the synaptosomes. Removal of extracellular calcium and addition of 
EGTA had no effect on the time course or magnitude of the ionophore-
induced release of propranolol. A three minute exposure of atenolol-
loaded synaptosomes to A23187 (1.0 J.JM) in the presence of calcium 
released approximately 14.5 ± 2.2% of the accumulated drug (Figure 
24). Removal of extracellular calcium and addition of EGTA (2.0 roM) 
reduced the A23187-induced release of atenolol to 7.5 ± 1.8%, a 
value that represented a reduction of 48%. 
Effect of 6-Hydroxydopamine Pretreatment on Drug Release 
To examine the contribution of adrenergic nerve terminals to 
the accumulation and release of propranolol and atenolol in synapto-
somes, rats were pretreated centrally with 6-hydroxydopamine to 
destroy adrenergic nerve endings in the brain. Pretreatment of the 
rats with 6-hydroxydopamine reduced the endogenous norepinephrine 
levels in the cerebral cortex 87.6%, from control values of 135.8 ± 
4.9 ng/g tissue to 16.8 ± 8.9 ng/g tissue in treated animals. 
Treatment with 6-hydroxydopamine did not significantly influence the 
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synaptosomal steady-state accumulation or the potassium-induced 
release of either propranolol or atenolol (Table 4). 
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DISCUSSION 
Two beta-adrenoceptor antagonists, the highly lipophilic drug 
propranolol and the more hydrophilic and cardioselective agent 
atenolol, were both accumulated by rat cortical synaptosomes, but 
there were differences between the two compounds in their rates of 
accumulation and in the steady-state levels attained. In contrast 
to the rapid accumulation of propranolol, which reached a steady 
state level of 20 pmoles/mg synaptosomal protein within one minute, 
atenolol was accumulated at a much slower rate and an equilibrium 
concentration of 0.6 pmol/mg protein was attained after 15 minutes 
of incubation. These findings probably reflect differences in the 
lipophilicity of the two drugs, propranolol having a log octanol/ 
water partition coefficient of 3.65, while the corresponding value 
for atenolol is 0.24 (Cruickshank, 1980). Neither propranolol nor 
atenolol appears to be a substrate for the biogenic amine uptake 
system since uptake of drug was not stereoselective, was insensitive 
to cocaine and ouabain (Saelens et al., 1977; Street et al., 1984; 
Street, unpublished observations) and was not reduced by pretreatment 
with 6-hydroxydopamine. For atenolol, the synaptosome/medium distri-
bution ratio of 1.0 to 1.4 supports this concept and is consistent 
with the passive equilibration of atenalol between intracellular and 
extracellular water. For propranolol, a synaptosome/medium distri-
bution ratio in the range 33 to 50 was estimated, suggesting that 
propranolol is concentrated by the synaptosome, an observation which 
may reflect binding of drug to cellular proteins (Barber et al., 
1978; Muller and Stillbauer, 1983) and membrane phospholipids 
(Dachary-Prigent et a1., 1979; Surewicz and Leyko, 1981). Conversely, 
59 
atenolol, a much more hydrophilic molecule, does not bind substan-
tially to proteins (Barber et al., 1978) or membrane phospholipids 
(Lullmann and Wehling, 1979). 
Both propranolol and atenolol were released from synaptosomes 
by elevated concentrations of potassium or veratridine. The time 
course of potassium-induced norepinephrine release was measured as 
an index of exocytosis and compared to the time courses of potassium-
induced propranolol and atenolol release from the synaptosomes. 
Release of both atenolol and norepinephrine was continuous over the 
time periods examined and appeared to increase linearly after the 
ini tial time point at 30 or 60 seconds. In contrast, propranolol 
release was rapid and completed within 15-30 seconds. The fractional 
release of propranolol and atenolol were both within the range of 
20-25% at two minutes and the absolute amounts of propranolol, 
atenolol and norepinephrine released ranged from 1.0-6.0 pmol/mg 
synaptosomal protein. It should be emphasized that in the atenolol 
release experiments, a loading concentration of 1.0 ~M was used as 
compared to a concentration of 0.1 ~M for propranolol and norepin-
ephrine. This is not unreasonable in view of the fact that thera-
peutic plasma levels of atenolol are as much as ten-fold higher than 
therapeutic levels of propranolol, particularly when the concentra-
tions of free drug in plasma are considered (Amery et al., 1977; 
Walle et al., 1978). 
In experiments designed to determine whether the release of the 
beta receptor blocking drugs by potassium was indeed a result of 
membrane depolarization, the relative potencies of potassium and 
other alkali metal ions to depolarize synaptosomal membranes were 
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compared with their ability to release propranolol. It is known 
that members of the alkali metal ion series depolarize exci table 
tissue to different extents (Shanes, 1958; Sjodin, 1959; Adrian and 
Slayman, 1966) such that the depolarization induced by potassium 
equals that of rubidium and is greater than that induced by equal 
concentrations of cesium in squid axon (Adelman and Senft, 1968). In 
synaptosomes, the potential difference across the plasma membrane 
approximates the potassium diffusion potential (Blaustein and Goldring, 
1975) and changes in membrane potential induced by members of the 
alkali metal ion series have been monitored as changes in fluorescence 
of the voltage-sensitive dye, 3,3'-dipentyl 2,2'-oxacarbocyanine 
(diO-CS-(3)) (Blaustein and Goldring, 1975). Rubidium was found to 
be equipotent to potassium in depolarizing the synaptosomal membrane 
and these ions were approximately four-fold more potent than equal 
concentrations of cesium. These results are in close agreement with 
those reported by Kamino and Inouye (1978), who demonstrated similar 
potency ratios for alkali metal ions in the depolarization of isolated 
synaptic plasma membrane ghosts as measured by the impermeant dye, 
merocyanine-540. 
Membrane potential changes in the present studies were monitored 
using the voltage-sensitive dye, 3,3'-dipropyl 2,2'-thiocarbocyanine 
(diS-C
3
-(5)). This dye offers the advantages of providing a large 
and reasonably fast change in fluorescence in response to changes in 
membrane potential, and because of this large signal, it can be used 
in low concentrations which do not influence the physiological 
parameters of the membrane, such as sodium and potassium fluxes 
(Sims et al., 1974). The positively charged dye is accumulated by 
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cells upon hyperpolarization and released upon depolarization. 
Cell-associated dye is less fluorescent than the dye in the medium, 
a result of aggregation of the cell-associated dye. The alkali 
metal ion potency ratios found for depolarization of the synapto-
somal membrane were in close agreement with those reported by 
Blaustein and Goldring (1975) in that potassium and rubidium were 
equipotent while cesium was three-fold less potent than the other 
two ions in producing membrane depolarization. Moreover, a similar 
potency ratio was observed for the action of these ions to release 
propranolol from synaptosomes. A strong positive correlation was 
found between the degree of synaptosomal membrane depolarization 
produced by individual ions and the action of these ions to promote 
propranolol release. It was also observed that 75 roM cesium was 
required to produce atenolol release equivalent to that induced by 
25 roM potassium. These observations are consistent with the idea 
that the release of both propranolol and atenolol from synaptosomes 
by potassium and the other alkali metal ions was the result of 
membrane depolarization. It is also noteworthy that elevated potassium 
does not cause the release of propranolol from myelin or mitochondria 
(Street et al., 1984) , the principal contaminants of synaptosome 
preparations, nor does it depolarize these components (Blaustein and 
Goldring, 1975). 
That release of propranolol and atenolol is a consequence of 
membrane depolarization is also supported by the series of experi-
ments with veratridine and tetrodotoxin. Veratridine depolarizes 
membranes by increasing membrane permeability to sodium (Catterall, 
1980), an action which is antagonized by tetrodotoxin (Ohta et al., 
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1973). In the present experiments, tetrodotoxin, in a concentration 
which almost totally inhibited the veratridine-induced release of 
norepinephrine, antagonized veratridine-induced propranolol release 
but did not abolish the response. The tetrodotoxin-sensitive com-
ponent of propranolol release is presumably related to depolariza-
tion, consistent with the observation that release promoted by 
alkali metal ions was in proportion to their depolarizing ability. 
The tet rodotoxin - ins ens i ti ve component 0 f vera tridine- induced pro-
pranolol release may represent an interaction between veratridine 
and propranolol unrelated to depolarization, possibly a displacement 
of propranolol from membranes by the lipophilic veratridine molecule. 
Propranolol has been shown to bind to biological membranes and model 
membrane systems (Huunan-Seppala, 1972; Godin et al., 1976; Lee, 
]977; Herbette et al., 1983) and membrane interactions between pro-
pranolol and other lipophilic amines have been demonstrated (Dollery 
and Junod, 1976; Vestal et a1., 1980; Hemsworth and Street, 1981; 
Rudnick et al., 1981). 
In experiments with atenolol, the veratridine-induced release 
of drug was effectively ab~lished by tetrodotoxin, suggesting that 
the release of atenolol by veratridine is principally the result of 
membrane depolarization. This observation is consistent with the 
results of the atenolol accumulation experiments which suggest 
little binding of atenolol to synaptosomal membranes. Quantita-
tively, it is also interesting to note that the percentage of atenolol 
released by veratridine approximates the tetrodotoxin-sensitive 
component of propranolol release, implying that the magnitude of 
depolarization-induced release of both beta blockers was similar. 
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Propranolol (pKa 9.45) and atenolol (pKa 9.6) are weak bases 
whose relative distributions across cell membranes and within cellular 
compartments should be influenced by pH gradients. It is conceivable, 
particularly with the lipophilic propranolol, that depolarization-
induced changes in synaptosomal pH could contribute to the increased 
drug efflux observed with increased extracellular potassium or 
veratridine. To test this possibility, potassium-induced release of 
propranolol or atenolol was examined in the presence of the proton 
ionophore, CCCP. CCCP had no effect on the basal release of pro-
pranolol from the synaptosomes but significantly enhanced potassium-
induced propranolol release. This finding is consistent wi th the 
report that during neuronal depol~rization slight acidification of 
the intracellular space occurs (Boron and Russell, 1983), an effect 
which would be enhanced by the reduction in extracellular sodium 
that accompanied the increase in potassium concentration in the 
present experiments. CCCP, by preventing the accumulation of intra-
cellular protons during membrane depolarization, should promote 
propranolol efflux from the synaptosome. The finding that CCCP did 
not increase the potassium-induced release of atenolol may reflect 
the fact that atenolol is a much more bydrophilic molecule than 
propranolol and, therefore, would redistribute across synaptosomal 
membranes very slowly. The data indicate that changes in intra-
synaptosomal pH occurring during membrane depolarization do not 
contribute to the potassium-induced release of propranolol or atenolol 
from synaptosomes and may actually impair the release of the rapidly 
equilibrating propranolol molecule. 
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Comparison of the calcium dependence of potassium-induced 
release of propranolol, atenolol and norepinephrine indicated that 
the release of all three molecules was influenced by extracellular 
calcium. As was the case for norepinephrine, the potassium-induced 
release of atenolol was largely calcium-sensitive. However, approxi-
mately 60% of potassium-induced propranolol release was independent 
of external calcium. The mechanism of propranolol release thus 
appears complex and it is possible that propranolol is released by a 
combination of processes. The calcium-dependent component of release 
may reflect exocytosis, while the release occurring in the absence 
of extracellular calcium may correspond to a nonexocytotic release 
mechanism. Alternatively, propranolol may be released solely by a 
nonexocytotic process which is sensitive to calcium but not entirely 
dependent on calcium for release to occur. The apparent complexity 
of synaptosomal propranolol release may reflect the fact that pro-
pranolol distributes within multiple compartments of the synaptosome 
and has been localized to the cytoplasm and synaptic plasma membrane 
as well as the synaptic storage vesicles (Street et a1., 1984). 
Conceivably, propranolol may be released from any of these sites as 
a result of perturbations associated with a depolarizing event. A 
further consideration is the possibility that the results are compli-
cated by the heterogeneous population of nerve terminals and non-neural 
elements present in the synaptosome preparation. 
The divalent cation ionophore, A23187, has been shown to 
stimulate the release of neurotransmitter from synaptosomes (Colburn 
et al., 1975; Holz, 1975; DeLangen and Mulder, 1980). Such release 
appears to result from the enhanced influx of calcium ions and can 
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occur with only minimal changes in membrane potential. For example, 
a three minute exposure to A23187 was reported to produce a 5.0 mV 
depolarization of the synaptosomal membrane (Akerman and Nichols, 
1981). In the present experiments, A23187, promoted the release of 
both propranolol and atenolol from the synaptosome preparation. The 
ionophore released 60% of the propranolol accumulated by the synapto-
somes, a value twice that observed with 75 DIM potassium. Iono-
phore-induced release of propranolol, however, was insensitive to 
external calcium, and appears to reflect an action of A23187 unrelated 
to its ability to stimulate calcium influx. In comparison, A23187-
induced release of atenolol from preloaded synaptosomes was similar 
in magnitude to that produced by potassium and showed calcium depen-
dence equivalent to that found for ionophore-induced norepinephrine 
release. The finding of calcium-dependent release of atenolol in 
the absence of a significant change in membrane potential supports 
the hypothesis that the calcium-dependent component of potassium-
induced atenolol release is indeed, like norepinephrine, due to an 
exocytotic mechanism. That the ionophore-induced release of atenolol 
or norepinephrine was not completely inhibited by the removal of 
extracellular calcium and addition of EGTA may reflect the ability 
of the ionophore to release calcium from mitochondria (Reed and 
Lardy, 1972) or other intracellular organelles. 
Previously reported data from in situ experiments suggested 
that propranolol may be released from adrenergic neurons in response 
to nerve stimulation (Daniell et al., 1979; Russell et al., 1983). 
This observation was supported further by the finding that pro-
pranolol was also released from cultured sympathetic ganglia by 
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field stimulation (Chapter II). However, destruction of the adre-
nergic nerve terminals in the synaptosome preparation by pretreatment 
with 6-hydroxydopamine did not significantly influence the accumu-
lation or release of propranolol or atenolol. Thus, depolarization-
induced release of beta receptor blocking drugs from this preparation 
does not require intact adrenergic nerve terminals which in cortical 
synaptosomes comprise only 5% of the neuronal population (Iversen 
and Schon, 1972). The demonstrated release of propranolol and 
atenolol from 6-hydroxydopamine-treated synaptosomes does argue 
against a specific and exclusive interaction of these drugs with 
adrenergic nerve terminals and extends the site of their release to 
include nonadrenergic neurons. Synaptosomes from cerebral cortex 
appear to be derived principally from cholinergic, y-aminobutyric 
acid-containing nerve endings and also tryptaminergic neurons 
(Bradford, 1975; Iversen and Bloom, 1972), all of which are resistant 
to 6-hydroxydopamine treatment (Kostrzewa and Jacobowitz, 1974). 
Anyone or all of these types of terminals could represent a site of 
drug release from the synaptosome preparation. In this regard, it is 
of interest that propranolol has been reported to influence trypta-
minergic, GABAminergic and cholinergic neurotransmitter mechanisms. 
For example, propranolol has been shown to inhibit the binding of 
radioligands used to characterize SHT
1 
receptors (Middlemiss et al., 
1977) as well as 5HT
2 
receptors (Green et al., 1983) and to modify 
behavioral responses mediated by 5-HT (Weinstock et al., 1977; 
Costain and Green, 1978). In addition t propranolol was reported to 
inhibit the uptake of y-aminobutyric acid by rat cortical slices 
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(Harris et a1., 1973) and upon acute withdrawal to increase choline 
uptake in rat brain striatum (Murrin et a1., 1983). 
In summary, the results of this study demonstrate that both 
propranolol and atenolol are accumulated by synaptosomes and are 
released in response to membrane depolarization. The release of two 
molecules with such widely differing physicochemical properties but 
each containing the characteristic beta blocking side chain supports 
the concept that neural storage and release may be a phenomenon 
common to beta receptor blocking drugs as a class. However, it 
remains to be determined whether the release mechanisms involved are 
selective for molecules with the beta blocking side chain or are 
operative for other drug molecules as well. In addition, the finding 
that propranolol and atenolol appear to be released from nonadrenergic 
as well as adrenergic neurons extends the possibility that these 
drugs may influence multiple transmitter systems. 
CHAPTER IV 
GENERAL DISCUSSION 
Exocytosis represents the best defined and most generally 
accepted mechanism for the secretion of a variety of neurotrans-
mitters, hormones, enzymes and proteins (Douglas, 1968). EXQcytosis 
is a calcium-dependent process and is believed to involve the extru-
sion of all the soluble contents of storage vesicles. For example, 
In adrenomedullary chromaffin cells, stimulation evokes the release 
of ATP, dopamine-beta-hydroxylase and chromogranin A along with 
catecholamines. Recent evidence suggests that opioid peptides are 
also stored within chromaffin granules and cosecreted in a calcium-
dependent manner in response to depolarizing stimuli (Viveros et 
al., 1979; Viveros e~ al., 1983). The precise role of the calcium 
ion in the events of exocytosis remains unknown. Calcium is proposed 
to link stimulation to secretion by promoting fusion of the vesicular 
and plasma membranes or to activate contractile proteins associated 
with the synaptic vesicle to initiate synaptic vesicle movement or 
promote the extrusion of the vesicular contents (Rubin, 1982). 
While the calcium-dependence of a release process is often 
taken as evidence for exocytotic events, it appears that calcium-
dependent but non-exocytotic mechanisms are also possible. The 
current concepts of acetylcholine release present an example. The 
release of acetylcholine from neurons is calcium-dependent but the 
mechanism responsible is controversial. In contrast to norepi-
nephrine, acetylcholine exists within nerves in cytoplasmic as well 
as vesicular pools (Israel and Dunant, 1979; Israel and Lesbats, 
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1981). Release from the vesicular pool via exocytosis could account 
for the quantal release of acetylcholine observed and is supported 
by morphological evidence. However, choline acetyltransferase, the 
enzyme responsible for acetylcholine synthesis, is localized in the 
cytoplasm of cholinergic neurons and newly synthesized transmitter 
is released preferentially (Collier, 1969; Potter, 1970). Moreover, 
no mechanisnl has been demonstrated for the rapid accumulation of 
acetylcholine by storage vesicles. These findings and the lack of 
stoichiometric release of ATP present within the vesicles along with 
the neurotransmitter support the possibility of calcium-dependent 
but nonexocytotic release of acetylcholine from a cytoplasmic pool 
(Kato et al., 1974; Michaelson, 1978). It has been proposed that an 
intrasynaptic receptor with high affinity binding sites exposed to 
the axoplasm exists for acetylcholine and that calcium may activate 
a gating mechanj -~j,;! which allows this acetylcholine to be released 
(Tauc, 1982) . The most direct evidence of a calcium-dependent 
nonexocytotic release mechanism for acetylcholine, however, has been 
demonstrated using proteoliposomes. Proteoliposomes are a synapto-
some-derived membrane preparation devoid of synaptic storage vesicles 
which, nonetheless, release acetylcholine in response to depolariza-
tion in a calcium-dependent manner (Meyer and Cooper, 1983). Another 
recent finding which may form the basis of a calcium-dependent 
nonexocytotic release mechanism is the demonstration of a calcium-
sensitive acidic glycoprotein in the cytoplasm of rat brain synapto-
somes. The glycoprotein molecule avidly binds dopamine and releases 
the amine in response to elevated calcium (Tsudzuki, 1983). 
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Calcium-independent nonexocytotic release mechanisms have also 
been descri ned for endogenous substances, particularly the amino 
acid neurotransmitters. For example, taurine, a putative neurotrans-
mitter substance, is released from synaptosomes by a calcium-inde-
pendent mechanism (Sieghardt and Heckl, 1976). Data have also been 
generated to support such a calcium-independent mechanism for a 
fraction of the y-aminobutyric acid released from synaptosomes in 
response to elevated potassium (Haycock et a~., 1978) or veratridine. 
In addition, there is no evidence to support the storage of these 
amino acids in synaptic vesicles (Mulder, 1982), and it has been 
reported that the release of amino acid neurotransmitters induced by 
either potassium or veratridine occurs principally from cytoplasmic 
pools (DeBelleroche and Bradford, 1977). These data are consistent 
with a nonexocytotic release mechanism operating for amino acid 
neurotransmitters, a mechanism that has some specificity in that not 
all cytoplasmic amino acids are released when neurons are depolarized 
(Bradford, 1975; Mulder and Snyder, 1976; DeBelleroche and Bradford, 
1977). 
In summary, multiple mechanisms have now been proposed to 
explain the stimulus-induced release of neurotransmitters and neuro-
modulators (Figure 25). Exocytosis, the best characterized of these 
mechanisms, is calcium-dependent and represents the principal process 
for the release of molecules localized within storage granules. In 
addition, it is clear that alternative nonexocytotic release pro-
cesses also contribute to the release of specific molecules. Such 
mechanisms may be calcium-dependent or calcium-independent and 
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participate in the release of molecules localized to the cytoplasm 
and possibly other sites within the cell. 
Propranolol shows a complex distribution in synaptosomes and is 
found in association with synaptic plasma membranes, synaptic storage 
vesicles and the cytoplasmic fraction (Street et al_, 1984). The 
drug also readily binds to membrane phospholipids and glycoproteins. 
Thus, propranolol would appear to be a candidate for many of the 
release mechanisms that have been proposed. The calcium-dependent 
component of propranolol release possibly represents exocytotic 
release of drug in response to membrane depolarization. This state-
ment is supported by the demonstrated interaction of propranolol 
with adrenergic storage vesicles that resulted in the release of 
norepinephrine (Daniell et al., 1976; Saelens et al., 1977). Pro-
pranolol should accumulate within synaptic storage vesicles based on 
its lipophilicity, pKa of 9.45 and the intravesicular pH of 5.8 
(Henry and Wyllie, 1981). In fact, propranolol was localized to 
synaptic vesicles in the subcellular localization studies conducted 
by Street and coworkers (1984) and was found there in an amount 
equal to 16% of the total synaptosome-associated drug. If in the 
vesicle, presumably propranolol could be released by exocytosis. An 
argument against propranolol's release by an exocytotic mechanism is 
based on the characteristics of the drug's release from synaptosomes. 
The time course of release of propranolol was very rapid and complete 
within 15-30 seconds. This was considerably different from the time 
course of norepinephrine release and would seem inconsistent with 
the mechanics of secretion. This interpretation is made with the 
assumption that norepinephrine release in these studies reflects 
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exocytosis from all cell types. Conceivably, the calcium-dependent 
component of propranolol release may not represent exocytosis but, 
instead, reflect a calcium-dependent but nonexocytotic process such 
as the gating mechanism that has been proposed for acetylchol ine 
(Tauc, 1982) or release from a cytoplasmic acid glycoprotein in 
response to 
1983). The 
calcium as has been described for dopamine (Tsudzuki, 
latter possibility is SUPI)orted by the finding that 
propranolol readily binds to protein (Barber et a1., 1978) particu-
larly an aI-acid glycoprotein in plasma (Muller and Stillbauer, 
1983). The extent that this may occur to similar proteins in cyto-
plasm of nerve endings is not known. 
Propranolol was also released by calcium-independent processes 
from both the cultured ganglia and rat cortical synaptosomes. These 
observations presumably represent nonexocytotic mechanisms of drug 
release from the cytoplasm or perhaps synaptic plasma membrane, the 
site of the greatest propranolol concentration in the synaptosome. 
Too little is known about such mechanisms to allow speculation about 
whether the process for propranolol is similar to that described for 
y-aminobutyric acid and other putative amino acid neurotransmitters. 
Atenolol, in contrast to propranolol, shows a relatively selective 
distribution within synaptosomes and is released primarily by a 
calcium-dependent process. Atenolol was found within the synaptosome 
in association with synaptic vesicles and in the cytoplasm (Street, 
unpublished observations). There was no indication of drug binding 
to the synaptic plasma membrane which is consistent with the lack of 
atenolol binding to membrane phospholipids (Liillman and Wehling, 
1979) or plasma proteins (Barber et a1., 1978). Thus, atenolol 
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would appear to be a candidate for only a limited number of the 
release mechanisms that have been proposed. The time course of 
atenolol release from synaptosomes was very similar to that demon-
strated for norepinephrine. In addition, the calcium-dependence of 
atenolol release by either potassium or the ionophore A23187 was 
also of the same degree as that observed for the neurotransmitter. 
These observations coupled with the localization of atenolol to 
synaptic storage vesicles support the hypothesis that. atenolol 
release from synaptosomes occurs principally by an exocytotic mecha-
nism. 
The release of propranolol from cultured sympathetic ganglia 
and synaptosomes is consistent with previous findings of propranolol 
release in association with sympathetic nerve stimulation in situ. 
Collectively, these observations make a strong case for the release 
of propranolol from nerve terminals in response to membrane depolari-
zation. The release of atenolol extends this concept to include 
polar beta receptor blocking drugs as well as the nonpolar propranolol 
molecule. The mechanisms by which these drugs are released are com-
plex. Propranolol was released principally by a calcium-independent 
mechanism while atenolol was released primarily by a calcium-dependent 
process. It. is not certain if the calcium-dependent component of 
release observed for both molecules represents a shared mechanism or 
two independent processes. Conclusions regarding these release 
mechanisms are further complicated by the heterogeneous nature of 
the synaptosome preparation and the fact that the types of nerve 
terminals with which the drugs interact is unknown. The use of a 
more homogeneous system of cells, such as adrenal medullary cells 
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where more selective pharmacological tools are available, may prove 
helpful 111 further del ineating the mechanisms of propranolol and 
atenolol release. The structural specificity of the release processes 
is also an open question. Although the neural release of both 
propranolol and atenolol has been demonstrated, it is not known 
whether the release mechanisms involved are selective for molecules 
with the beta blocking side chain or are operative for other molecules 
as well. A detailed study of the structural requirements for release 
will be necessary to address this question. Answers to such questions 
along with the findings of the present studies should ultimately 
provide an understanding of the contribution of neural storage and 
release mechanisms to the pharmacology of beta adrenergic receptor 
blocking drugs. 
76 
LIST OF REFERENCES 
o 
Ablad, B., M. Brogard and L. Ek. "Pharmacological properties of H56/28-a 
~-adrenergic recepLor antagonist." Acta pharmac. toxieol. 25 (Suppl. 
2):9-40, 1967. 
Adelman, W.J. and J.P. Senft. "Dynamic asymmetries in the squid axon 
membrane." J. gen. Physiol. 51:1025-1145, 1968. 
Adler-Graschinsky, E. and S.Z. Langer. "Possible role of a ~-adrenoceptor 
in the regulation of noradrenaline release by nerve stimulation 
through a positive feedback mechanism. u Br. J. Pharmac. 53: 43-50, 
1975. 
Adrian, R.H. and C.L. Slayman. "Membrane potential and conductance during 
transport of sodium, potassium and rubidium in frog muscle." J. Physiol., 
Lond. 184:970-1014, 1966. 
Ahlquist, R.P. "A study of adrenotropic receptors." Am. J. Physiol. 
153:586-600, 1948. 
Akerman, K.E.O. and D.G. Nicholls. ttCalcium transport in synaptosomes: 
Influence of ionophore A23187 on plasma-membrane potential, plasma-
membrane calcium transport, mitochondrial membrane potential, respira-
tion, cytosolic free-calcium concentration and noradrenaline release." 
Eur. J. Biochem. 115:67-73, 1981. 
American Druggist. "The top 200 prescription drugs of 1983." 2:42-50, 
1984. 
Amery, A. J. F. DePlaen, R. Fagard, P. Lijnen and T. Reybrouck. t'The 
relationship between beta-blockade, hyporeninacemic and hypotensive 
effect of two beta-blocking agents." Postgrad Med. J. 52(Suppl. 4): 
102-108, 1976. 
Amery, A., J.F. DePlaen, P. Lijnen, J. McAinsh and T. Reybrouck. ttRela-
tionship between blood level of atenolol and pharmacological effect." 
Clin. Pharmac. Ther. 21(6): 691-699, 1977. 
Barber, H.E., G.M. Hawsworth, N.R. Kitteringham, J. Petersen, J.e. Petrie 
and J.M. Swann. "Protein binding of atenolol and propranolol to 
human serum albumin and in human plasma." Br. J. clin. Pharmac. 
6:446P-447P, 1978. 
Barrett, A.M. and V.A. Cullum. "The biological properties of the optical 
isomers of propranolol and their effects on cardiac arrhythmias." 
Br. J. Pharmac. 34:43-55, 1968. 
Barrett, A.M. and B. Nunn. "Adrenergic neuron blocking properties of 
(±)-propranolol and (+)-propranolol. J. Pharm. Pharmac. 22:806-810, 
1970. 
77 
Baurn, T., G. Rowles, A.T. Shropshire and M.I. Gluckman. "Beta adrenergic 
blocking and cardiovascular properties of two new substances, Ko1313 
and KoI366." J. Pharmac. expo Ther. 176:339-349, 1971. 
Bjorntrop, P. "Treatment of angina pectoris with beta-receptor blockade, 
mode of action." Acta med. scand. 184:259-262, 1968. 
Black, J.W., A.F. Crowther, R.G. Shanks, L.R. Smith and A.C. Dornhorst. 
"A new adrenergic beta-receptor antagonist." Lancet 1:1080-1081, 
1964. 
Black, J.W. and J.S. Stephenson. "Pharmacology of a new adrenergic beta-
receptor-blocking compound (Nethalide)." Lancet 2:311-314, 1962. 
Blaustein, M.P. "Effects of potassium, veratridine and scorpion venom on 
calcium accumulation and transmitter release by nerve terminals in 
vitro." J. Physiol., Lond .. 247: 617-655, 1975. 
Blaustein, M.P. and J.M. Goldring. "Membrane potentials in pinched-off 
presynaptic nerve terminals monitored with a fluorescent probe: 
evidence that synaptosomes have potassium diffusion potentials." 
J. Physiol., Lond. 247: 589-615, 1975. 
Blaustein, M.P., R.M. Johnson, Jr. and P .. Needleman. "Calcium-dependent 
norepinehprine release from presynaptic nerve endings in vitro." 
Proc. nato. A~~d. Sci. U.S.A. 69(8): 2237-2240, 1972 .. 
Bogdanski, D.F., A. Tissari and B.B. Brodie. "Role of sodium, potassium, 
ouabain and reserpine in uptake, storage and metabolism of biogenic 
amines in synaptosomes." Life Sci. 7(1):419-428, 1968. 
Boron, W.F. and J.M .. Russell. "Stoichiometry and ion dependencies of the 
intracellular-pH-regulating mechanisms in squid giant axons." J. gen. 
Physiol. 81:373-399, 1983. 
Bradford, R.F. tfIsolated nerve terminals as an in vitro preparation for 
study of dynamic aspects of transmitter metabolism and release." In: 
Biochemical Principles and Techniques in Neuropharmacology, Ranb. 
Psychopharmac., Vol. 1, edited by L.L. Iversen, S.D. Iversen and S.D. 
Synder. New York: Plenum Press, 1975, pp. 191-252. 
Bradford, H.F., D.G. Jones, H.K. Ward and J .. Booher. "Biochemical and 
morphological studies of the short and long term survival of isolated 
nerve endings. tf Brain Res. 90:245-259, 1975. 
Buhler, F.R., J.H. Laragh, L. Baer, E.D. Vaughan and H.R. Brunner. 
"Propranolol inhibition of renin secretion." New Eng. J. Med. 287(24): 
1209-1214, 1972. 
Catterall, W.A. "Neurotoxins "that act on voltage-sensitive sodium channels 
in excitable membranes. Ann .. Rev. Pharmac. Toxicol. 20: 15-43, 1980. 
78 
Cohen, L.S. "Beta-blockade in the management of angina pectoris. tt In: 
Beta Adrenergic Blockade: A New Era in Cardiovascular Medicine: 
Proceedings of an International Symposium, edited by E. Braunwald. 
Amsterdam: Excepta Medical Elsevier, 1978, pp. 143-151. 
Colburn, R.W., N.B. Thoa and I.J. Kopin. "Influence of ionophores which 
bind calcium on the release of norepinephrine from synaptosomes." 
Life Sci. 17:1395-1400, 1975. 
Collier, B. "The preferential release of newly synthesized transmitter 
by a sympathetic ganglion." J. Physiol., Lond. 205: 341-352, 1969. 
Coltart, D.J. and D.G. Shand. "Plasma propranolol levels in the quanti-
tative assessment of ~-adrenergiC' blockade in man." Br. Med. J. 
3:731-734, 1970. 
Costain, D.W. and A.R. Green. tI~-adrenoceptor antagonists inhibit the 
behavioural responses of rats to increased brain 5-hydroxytryptamine." 
Br. J. Pharmac. 64:193-200, 1978. 
Cotman, C.W., J.W. Haycock and W.F. White. "Stimulus secretion coupling 
processes in brain: analysis of noradrenaline and gamma-aminobutyric 
acid release." J. Physiol. 254: 475-505, 1976. 
Cruickshank, J.M. liThe clinical importance of cardioselectivity and 
lipophilici ty in beta blockers. tt Am_. Heart J. 100 (2) : 160-178, 1980. 
Dachary-Prigent, J., J. Dufourcq, C. Lussan and M. Boisseau. "Propranolol, 
chlorpromazine and platelet membrane: a fluorescence study of the 
drug-membrane interaction." Thrombosis Res. 14: 15-22, 1979. 
Daniell, H.B., A.J. St. Pierre and J.G. Webb. "A positive inotropic 
effect of propranolol on the canine myocardium: a presynaptic effect." 
J. Pharmac. expo Ther. 196:657-664, 1976. 
Daniell, H.B., T. Walle, T.E. Gaffney and J.G. Webb. ffStimulation-induced 
release of propranolol and norepinephrine from adrenergic neurons." 
J. Pharmac. exp.Ther. 208: 354-357, 1979. 
Day, M.D., A.A. Owen and P.R. Warren. "An adrenergic neuron blocking 
action of propranolol in isolated tissues." J. Pharm. Pharmac. 
20(Suppl.):130S-134S, 1968. 
DeBelleroche, J.S. and H.F. Bradford. "The stimulus-induced release of 
acetylcholine from synaptosome beds and its calcium dependence." 
J. Neurochem. 19:1817-1819, 1972. 
DeBelleroche, J.S. and H.F. Bradford. "On the site of origin of trans-
mitter amino acids released by depolarization of nerve terminals in 
vitro." J. Neurochem. 29:335-343, 1977. 
79 
DeLangen, C. D. J". and A. H. Mulder. "On the role of calcium ions in the 
presynaptic alpha-receptor mediated inhibition of 3H-noradrenaline 
release from rat brain cortex synaptosomes." Brain Res. 185: 399-408, 
1980. 
DeLores Arnaiz; G.R. and E. DeRobertis. "Properties of Isolated Nerve 
Endings." In: Current Topics in Membrane and Transport, Vol. 3, 
edited by F. Bronner and A. Kleinzeller, New York: Academic Press, 
1972, pp. 237-272. 
DeRobertis, E., A.P. delraldi, G.R. deLores Arnaiz and L. Salganicoff. 
ttCholinergic and non-cholinergic nerve endings in rat brain-I." 
J. Neurochem. 9:23-35, 1962. 
Deutsch, C. and U. Rafalowska. "Transmembrane electrical potential 
measurements in rat brain synaptosomes." FEBS Letters 108(1):274-278, 
1979. 
Diamond, S. and J.L. Medina. "Headaches." Clin. Symp. 33(2):2-11, 1981. 
Dollery, C.T. and A.F. Junod. "Concentrations of (±)-propranolol in 
isolated perfused lungs of rats." Br. J. Pharmac. 57:67-71, 1976. 
Dornhorst, A.C. and B.F. Robinson. "Clinical pharmacology of a beta-
adrenergic-blocking agent (Nethalide)." Lancet 2:314-316, 1962. 
Douglas, W.W. "Stimulus-secretion coupling: the concept and clues from 
chromaffin and other cells." Br. J. Pharmac. 34:451-474, 1968. 
Dunlop, D. and R.G. Shanks. "Selective blockade of adrenoceptive beta 
receptors in the heart." Br. J. Pharmac. Chemother. 32:201-218, 
1968. 
Esler, M., G. Jackson, P. Leonard, H. Skews, A. Bobik and G. Jennings. 
"Effect of propranolol on noradrenaline kinetics in patients with 
essential hypertension. 1t Br. J. clin. Pharmac. 12:375-380, 1981. 
Ferrendelli, J.A. and S. Daniels-McQueen. "Comparative actions of pheny-
toin and other anticonvulsant drugs on potassium-and veratridine-
stimulated calcium uptake in synaptosomers." J. Pharmac. expo Ther. 
220(1):29-34, 1982. 
Fitzgerald, J.D. "Propranolol." In: 
Drugs, edited by A. Schriabine. 
195-208. 
Pharmacology of Antihypertensive 
New York: Raven Press, 1980, pp. 
Fleming, L.H., A.E. Hoduch and N.C. Reynolds. "Effects of isolation and 
incubation on the biochemical and morphological integrity of synapto-
somes." Brain Res. 202:469-473, 1980. 
Godin, D.V., T.W. Ng and J.M. Tucheck. "Studies on the interaction of 
propranolol with erythrocyte membranes. H Biochim. biophys. Acta 
436:757-773, 1976. 
80 
Gray, E.G. and V.P. Whittaker. "The isolation of nerve endings from 
brain: an electron microscopic study of cell fragments derived by 
homogenation and centrifugation. tt J. Anat. 96: 79-88, 1962. 
Green, A.R., P. Johnson and V.L. Nimgaonkar. "Interactions of ~-adreno­
ceptor agonists and antagonists with the 5-hydroxytryptamine (SHT
2
) 
receptor." Neuropharmacology 22(5):657-660, 1983. 
Gross, G.J. and M.M. Winbury. "Beta adrenergic blockade on intramyocardial 
distribution of coronary blood flow." J. Pharmac. expo Ther. 187: 
451-464, 1973. 
Raga, T. "Synthesis and release of [ 14C]acetylcholine in synaptosomes." 
J. Neurochem. 18:781-798, 1971. 
Hamer, J., T. Grandjean, L. Melendez and G.E. 
propranolol (Inderal) in angina pectoris: 
Br. med J. 2:720-723, 1964. 
Sowton. "Effect of 
Preliminary report." 
Hanbauer, I., D.G. Johnson, S.D. Silberstein and I.J. Kopin. Pharmaco-
logical and kinetic properties of uptake of [3H]-norepinephrine by 
superior cervical ganglia of rats in organ culture." Neuropharmacology 
11:857-862, 1972. 
Hanssen, T., T. Heyden, I. Sundberg, G. Alfredsson, H. Nyback and L. 
Wetterberg. "Propranolol in Schizophrenia." Archs. gen. P~chiat. 
37:685-690, 1980. 
Harris, M., J.M. Hopkin and M.J. Neal. "Effect of centrally acting drugs 
on the uptake of y-aminobutyric acid (GABA) by slices of rat cerebral 
cortex." Br. J. Pharmac. 47:229-239, 1973. 
Hawthorne, J.N. and M.R. Pickard. "Phospholipids in synaptic function." 
J. Neurochem. 32:5-14, 1979. 
Haycock.,. J.W., W.B. Levy, L.A. Denner and C.W. Cotman. "Effects of elevated 
[K] on the release of neurotransmitters from cortical synaptosomes: 
effl3.x or secretion?tt J. Neurochem. 30: 1113-1125, 1978. 
Hemsworth, B.A. and J.A. Street. "Characteristics of (±)_[ 14C]-oxprenolol 
and (±)_[ 14C]-propranolol incorporation by rat lung slices." Br. J. 
Pharmac. 73:119-125, 1981. 
Henry, D.P., B.S. Starman, D.G. Johnson and R.H. Williams. "A sensitive 
radioenzyrnic assay for norepinephrine in tissue and plasma." Life 
Sci. 16:375-384, 1975. 
Henry, J.A. and M.G. Wyllie. "A pH gradient may contribute to uptake 
into synaptosomes and synaptic vesicles." Br. J. Pharmac. 74:872-873P, 
1981. 
Herbette, L., A.M. Katz and J.M. Sturtevant. "Comparisons of the inter-
action of propranolol and timolol with model and biological membrane 
systems." Mol. Pharmac. 24:256-269, 1983. 
81 
Hirsch, S.R., R. Manchanda and N.P.I. Weller. ItDextro-propranolol in 
schizophrenia. tf Prog. Neuro-Psycl).opharmac. 4: 633-637. 
Hollifield, J., K. Sherman and D. Shand. "Propranolol's proposed dual 
antihypertensive activity." Circulation 52 (Suppl. 2): 98, 1975. 
Holz, R.W. "The release of dopamine from synaptosomes from rat striatim 
by ionophores X537A and A23187." Biochim. Biophys. Acta 375:138-152, 
1975. 
Horn, A.S. "Structure-acitivity relations for the inhibition of catehcol-
amine uptake into synaptosomes from noradrenaline and dopaminergic 
neurons in rat brain homogenates." Br. J. Pharmac. 47:332-338, 1973. 
Howe, R. and R.G. Shanks. "Optical isomers of propranolol." Nature, Lond. 
210:1336-1338, 1966. 
Huriwitz, G.A., J.G. Webb, T. Walle, S.A. Bai, H.B. Daniell, L. Gourley, 
C.B. Loadhold and T.E. Gaffney. "Exercise-induced increments in 
plasma levels of propranolol and noradrenaline." Br. J. clin. Pharmac. 
16:599-608, 1983. 
Huunan-Seppala, A. "Binding of propranolol and chlorpromazine by mito-
chondrial membranes." Acta chern. scand. 26:2713-2733, 1972. 
Israel, M. and Y. Dunant. "On the mechanism of acetylcholine release." 
In: The Cholinergic Synapse, Prog. in Brain Res., Vol. 49, edited 
by S. Tucek. New York: Elsevier Scientific, 1979, P.p. 125-139. 
Israel, M. and B. Lesbats. "Continuous determination by a chemiluminescent 
method of acetylcholine release and compartmentation in Torpedo 
electrical organ synaptosomes." J. Neurochem. 37(6):1475-1483, 1981. 
Iversen, L. L. and F'. E. Bloom. "Studies on the 
[3H]-glycine in slices and homogenates of 
by electron microscopic autoradiography.1t 
1972. 
uptake of [3Hl-GABA and 
rat brain and spinal cord 
Brain Res. 41:131-143, 
Iversen, L.L. and F.E. Schon. "The use of autoradiographic techniques for 
the identification and mapping of transmitter-specific neurones in 
eNS." In: New Concepts in Neurotransmitter Regulation, edited by 
A.J. Mandell. New York: Plenum Press, 1973, pp. 153-193. 
Iversen, L.L. and N.J. Uretsky. "Regional effects of 6-hydroxydopamine 
on catecholamine containing neurones in rat brain and spinal cord." 
Brain Res. 24:364-367, 1970. 
Jackson, E.K. and W.B. Campbell. "A possible antihypertensive mechanism 
of propranolol: Antagonism of angiotensin II enhancement of sympa-
thetic nerve transmission through prostaglandins." Hypertension 3: 
23-33, 1981. 
JAMA. "A randomized trial of propranolol in patients with acute myocardial 
infarction. I. Mortality results." 247(12):1707-1714, 1982. 
82 
Kamino, K. and A. Inouye. "Evidence for membrane potential changes in 
isolated synaptic membrane ghosts monitored with a rnerocyanine dye." 
Jap. J. Physiol. 28:225-237, 1978. 
Kato, A.C., H.S. Katz and B. Collier. "Absence of adenine nucleotide 
release from autonomic ganglion." Nature 249 :576-577, 1974. 
Kelliher, G.J. and J.P. Buckley. "Central hypotensive activity of dl-
and d-propranolol." J. Pharm. Sci. 59:1276-1280, 1970. 
Kopin, I.J., K.R. Berv and J.G. Webb. "Sympathetic Ganglia in Culture." 
In: Frontiers in Catecholamine Research, edited by E. Usdin and S.H. 
Snyder. New York: Pergamon Press, 1973, pp. 239-244. 
Kostrzewa, R.M. and D.M. Jacobowitz. "Pharmacological actions of 6-hydroxy-
dopamine." Pharmac. Rev. 26:199-288, 1974. 
Lands, A.M., A. Arnold, J.P. McAuliff, F.P. Luduena and T.G. Brown, Jr. 
"Differentiation of receptor systems activated by sympathomimetic 
amines." Nature 214:597-598, 1967. 
Langer, S.Z. "Presynaptic regulation of catecholamine release." Biochem. 
Pharmac. 23:1793-1800, 1974. 
Langer, S.Z. "Presynaptic receptors and their role in the regulation 
of transmitter release." Br. J. Pharmac. 60:481-497, 1977. 
Langslet, A. "Membrane stabilization and cardiac effects of d,l-propran-
0101, d-propranolol and chlorpromazine." Eur. J. Pharmac. 13:6-14, 
1970. 
Larabee, M.G. "Metabolism of adult and embryonic sympathetic ganglia." 
Fed. Proc. 29(6):1919-1928, 1970. 
Leaman, D.M. L.W. Levenson, R.A. Shiroff, J.D. Babb, R.L. Dejoseph, 
A.H. Hayes and R. Zelis. "Persistence of biologic activity after 
disappearance of propranolol from the serum." J. thorac. cardiovasc. 
Surge 72:67-72, 1976. 
Lee, A.G. "Local anesthesia: the interaction between phospholipids and 
chlorpromazine, propranolol and practolol." Mol. Pharmac. 13:474-487, 
1977. 
Ling, C.M. and A.A. Abdel-Latif. "Studies on sodium transport in rat 
brain nerve ending particles." J. Neurochem. 15:721-729, 1968. 
Lowry, D.H., N.J. Rosebrough, A.L. Farr and R.J. Randall. "Protein 
measurement with the folin phenol reagent.tt J. bioI. Chern. 193: 
265-275, 1951. 
Liillman, H. and M. Wehling. "The binding of drugs to different polar 
lipids in vitro." Biochem. Pharmac. 28:3409-3415, 1979. 
MacKay, A.V.P. and L.L. Iversen. "Trans-synaptic regulation 
hydroxylase activity in adrenergic neurons: Effect of 
concentration on cultured superior cervical ganglia." 





Marchbanks, R.M. "The uptake of [14C]choline into synaptosomes in vitro." 
Biochem. J. 110:533-541, 1968. 
Marquardt, G.M., J. Distefano and L. Ling. "Effects of racemic, (S)- and 
(R)-methylene deoxyamphetamine on synaptosomal uptake and release of 
norepineprhine." Biochem. Pharmac. 27:1497-1501, 1978. 
Mathew, N.T. "Prophylaxis of migraine and mixed headache: a randomized 
controlled study." Headache 21:105-109, 1981. 
Matthews, J.e. and J.K. Baker. "Effects of propranolol and a number of 
its analogues on sodium channels." Biochem. Pharmac. 31(9):1681-1685, 
1982. 
Medical Letter. "Beta-blockers after myocardial infaction." 24(608): 
43-44, 1982. 
Meyer, E.M. and J.R. Cooper. "High affinity choline uptake and calcium-
dependent acetylcholine release in proteoliposomes derived from rat 
cortical synaptosomes." J. Neurosci. 3 (5): 987-994, 1983. 
Michaelson, D.M. "Is presynaptic acetylcholine release accompanied by 
the secretion of the synaptic vesicles contents?" FEBS Letters 
89(1):51-53, 1978. 
Middlemiss, D.N., L. Blakeborough and S.R. Leather. "Direct evidence for 
an interaction of f3-adrenergic blockers with the 5-HT receptor." 
Nature 267:289-290, 1977. 
Moran, N.A. and M.E. Perkins. "Adrenergic blockade of the mammalian heart 
by a dichloro analogue of isoproterenol. tt J. Pharmac. expo Ther. 
124:223-237, 1958. 
Morganti, A., T.G. Pickering, J.A. Lopez-Ovejero and J.R. Laragh. 
"Contrasting effects of acute beta blockade with propranolol on 
plasma catecholamines and renin in essential hypertension: A possible 
basis for the delayed antihypertensive response." Am. Heart J. 
98:490-494, 1979. 
Mulder, A.H. "An overview of subcellular localization, release and 
termination of action of amine, amino acid and peptide neurotrans-
mitters in the CNS. 1t In: Progress in Brain Research, Volume 55, 
Chemical Transmission in Brain: Role of Amines, Amino Acids and 
Peptides, edited by R.M. Buijs, P. Pevet and D.F. Swaab. New York: 
Elsevier Biomedical Press, 1982, pp. 135-156. 
Mulder, A.H. and S.H. Synder. ttPutative Central Neurotransmitters." 
In: Molecular and Functiona~_. Neurobiol~, edited by W.H. Gispen. 
Amsterdam: Elsevier, 1976, pp. 161-200. 
84 
Muller, W.E. and A.E. Stillbauer. "Characterization of a common binding 
site for basic drugs on human aI-acid glycoprotein (orosomucoid)." 
Naunyn-Schmiedeberg's Arch. Pharmac. 322:170-173, 1983. 
Murrin, L. Charles, R.H. Kennedy and T.E. Donnelly, Jr. ttEffect of 
withdrawal from chronic propranolol treatment on high affinity choline 
uptake in rat brain." J. Pharm. Pharmac. 35:677-679, 1983. 
Nickerson, M. and L.S. Goodman. "Pharmacological properties of a new 
adrenergic blocking agent: N,N-dibenzyl-~-chloroethylamine (Diben-
amine)." J. Pharmac. exp Ther. 89:167-185, 1947. 
Nies, A.S. and R.L. Woosley. "The non-beta-adrenergic blocking actions of 
propranolol." In: Beta-adrenergic blockade: A New Era in Cardio-
vascular Medicine: Proceedings of an International Symposium, edited 
by E. Braunwald. Amsterdam: Excepta Medical Elsevier, 1978, pp 
113-130. 
Noack, E., M. Kurzmack, S. Verjovski-Alm2ida and G. Inesi. "The effect of 
propranolol and its analogues on Ca transport by sarcoplasmic 
reticulum vesicles." J. Pharmac. expo Ther. 206:281-288, 1979. 
Noble, E.P., R.J. Wurtman and J. Axelrod. "A simple and rapid method for 
injecting 3H-norepinephrine into the lateral ventricle of the rat 
brain." Life Sci. 6:281-291, 1967. 
Ohta, M., T. Narahashi and R.F. Keeler. ttEffects of veratrum alkaloids on 
membrane potential and conductance of sqUid and crayfish giant axons. 
J. Pharmac. expo Ther. 184: 143-154, 1973. 
Olson, L. and T. Malmfors. 
in the adult rat. tt 
"Growth characteristics of adrenergic nerves 
Acta physiol. scand. Supple 348, 1970. 
Paget, G. E. : ttCarcinogenic action of pronethalol." 
2:1266-1267, 1963. 
Br. med. J. 
Pappu, A.S. and G. Hauser. "Alterations of phospholipid metabolism in 
rat cerebral cortex mince induced by cationic amphiphilic drugs." 
J. Neurochem. 37(4):1006-1014, 1981a. 
Pappu, A.S. and G. Hauser. "Changes in polyphosphoinositide metabolism 
induced by cationic amphiphilic drugs in vitro." Biochem. Pharmac. 
30(23):3242-3246, 1981b. 
Pappu, A.S. and G. Hauser. "Phospholipid metabolism changes in rat tissues 
in vitro after injections of propranolol. 1t J. Pharmac. expo Ther. 
222(1):109-115, 1982. 
Patterson, E., P. Stetson and B.R. Lucches: "Plasma and myocardial tissue 
concentrations of UM-272 (N,N-dimethylpropranolol) after oral admin-
istration in dogs." J. Pharmac. expo Ther. 214: 449-453, 1980. 
Peet, M. "Is Propranolol Antischizophrenic?" Neuropharmacology 20: 
1303-1307, 1981. 
85 
Pickard, M.R. and J.N. Hawthorne. "The labelling of nerve ending phospho-
lipids in guinea pig brain in vivo and the effect of electrical 
stimulation on phosphotidylinositol metabolism in prelabelled synapto-
somes." J. Neurochem. 30:145-155, 1978. 
Pitt, B. and P. Craven. "Effect of propranolol on regional myocardial 
blood flow in acute ischemia." Cardiovasc. Res. 4:176-179, 1970. 
Potter, L.T. "Synthesis, storage and release of [ 14C]acetylcholine in 
isolated rat diaphragm muscles." J. Physiol., Land. 206:145-166, 
1970. 
Powell, C.E. and I.H. Slater. "Blocking of inhibitory adrenergic 
receptors by a dichloro analog of isoproterenol." J. Pharmac. expo 
Ther. 122:480-488, 1958. 
Prichard, B.N.C. "Hypotensive action of pronethalol." Br. med. J. 1:1227-
1228, 1964. 
Prichard, B.N.C. "f)-adrenergic receptor blocking drugs in angina pectoris." 
Drugs 7:55-84, 1974. 
Prichard, B.N.C., M.E. Connolly, D.G. Shand and J.A. Oates. "The 
Clinical Pharmacology of Antihypertensive Drugs: Beta-adrenoceptor 
Blocking Drugs." In: Antihypertensive Agents, Hanb. expo Pharmac., 
Vol. 39, edited by F. Gross. New York: Springer-Verlag, 1977, pp 
589-606. 
Prichard, B.N.C., C.J. Dickinson, G.A.O. Alleyne, P. Hurst, I.D. Hill, 
M.L. Rosenheim and D.R. Laurence. "Effect of pronethalol in angina 
pectoris." Br. med. J. 2:1226-1227, 1963. 
Prichard, B.N.C. and P.M.S. Gillam. 
treatment of hypertension." 
HUse of propranolol (lnderal) in 
Br. med. J. 2:725-727, 1964. 
Prichard, B.N.C. and P.M.S. Gillam. "Treatment of hypertension with 
propranolol." Br. med. J. 1:7-16, 1969. 
Privitera, P.J., J.G. Webb and T. Walle. ttEffects of centrally admin-
istered propranolol on plasma renin activity, plasma norepinephrine 
and arterial pressure." Eur. J. Pharmac. 54:51-60, 1979. 
Pruett, J.K., T. Walle and E.E. Bagwell. "Association of in vivo and 
in vitro propranolol levels in canine purkinje fibers with anti-
arrhythmic effects." J. Pharmac. expo Ther. 202(1):45-54, 1977. 
Rahn, K.H., W.H. Gierlichs, G. Planz, R. Planz, M. Schols and W. Stephany. 
"Studies on the effects of propranolol on plasma catecholamine levels 
in patients with essential hypertension." Eur. J. clin. Invest. 
8:143-148, 1978. 
Rahn, K.H., A. Hawlina, F. Kersting and G. Planz. "Studies on the anti-
hypertensive action of the optical isomers of propranolol in man." 
Naunyn-Schmiedeberg's Arch. Pharmac. 286:319-323, 1974. 
86 
Raiteri, M. and G. Levi. HRelease Mechanisms for Catecholamines and 
Serotonin in Synaptosomes." Reviews of Neuroscience, Volume 3, 
edited by S. Ehrenpreis and I. Kopin. New York: Raven Press, 1978, 
pp. 77-130. 
Reed, P.W. and H.A. Lardy. "A23187: A divalent cation ionophore. tt 
J. bioI. Chern. 247(21):6970-6977, 1972. 
Reele, S.B., D. Kornhauser, D. Shand, K. Carr, J.A. Oates and R.L. Woolsey. 
"Antiarrhythmic effects of the quaternary propranolol analog that 
does not induce beta-adrenergic blockade." Clin. Pharmac. Ther. 
32(1):33-40, 1982. 
Rubin, R.P. "The role of calcium in the release of neurotransmitter 
substances and hormones." Pharmac. Rev. 22(3):389-428, 1970. 
Rubin, R.P. "Nature of the role of calcium 
Calcium and Celular Secretion. New York: 
pp. 179-196. 
in secretion." 
Plenum Pres s , 
In: 
1982, 
Rudnick, G., R. Bencuya, P.J. Nelson and R.A. Zito, Jr. "Inhibition of 
platelet serotonin transport by propranolol." Mol. Pharmac. 20: 
118-123, 1981. 
Russell, M.P., J.G. Webb, T. Walle, H.B. Daniell, P.J. Privitera and 
T.E. Gaffney. "Adrenergic nerve stimulation-induced release of 
propranolol from the perfused hindlimb and spleen of the dog and 
associated changes in post junctional response." J. Pharmac. expo 
Ther. 226(2):324-329, 1983. 
Saelens, D.A., H.B. Daniell and J.G. Webb. 
propranolol with adrenergic neurons." 
635-645, 1977. 
"Studies on the interaction of 
J. Pharmac. expo Ther. 202: 
Schriabine, A. "f3-adrenoceptor blocking drugs in hypertension." Ann. Rev. 
Pharmac. Toxicol. 19: 269-284, 1979. 
Shand, D.G. ttPharmacokinetic properties of the f3-adrenergic receptor 
blocking drugs.: Drugs 7:39-47, 1974. 
Shand, D. G. "Propranolol." New Eng. J. Med. 293: 280-285, 1975. 
Shanes, A.M. "Electrochemical aspects of physiological and pharmaco-
logical action in excitable cells. Part 1. The resting cell and its 
alteration by extrinsic factors." Pharmac. Rev. 10:59-164, 1958. 
Sieghart, W. and K. Heckl. "Potassium-evoked release of taurine from 
synaptosomal fractions of rat cerebral cortex." Brain Res. 116: 
538-543, 1976. 
Silberstein, S.D., D.G. ·Johnson, D.M. Jacobowitz and I.J. Kopin. 
"Sympathetic reinnervation of the rat iris in organ culture." 
Proc. natn. A~~d. Sci. U.S.A. 68(6):1121-1124, 1971. 
87 
Silberstein, S.D., S. Brimijoin, P.B. Molinoff and L. Lemberger. 
ftInduction of dopamine-~-hydroxylase in rat superior cervical ganglia 
in organ culture." J. Neurochem. 19:919-921, 1972a. 
Silberstein, S.D., D.J. Johnson, I. Hanbauer, F.E. Bloom and I.J. Kopin. 
"Axonal sprouts and 3H-norepinephrine uptake by superior cervical 
ganglia in organ culture." Proc. natn. Acad. Sci. U.S.A. 69(6): 
1450-1454, 1972b. 
Sims, P.J., A.S. Waggoner, C. Wang and J.F. Hoffman. "Studies on the 
mechanism by which cyanine dyes measure membrane potential in red 
blood cells and phosphotidylcholine vesicles." Biochemistry. 13(16): 
3315-3330, 1974. 
Singh, B.N. and D.E. Jewitt. "~-adrenergic receptor blocking drugs in 
cardiac arrhythmias." Drugs 7:426-461, 1974. 
Sjodin, R.A. "Rubidium and cesium fluxes in muscle as related to the 
membrane potential." J. gen. Physiol. 42(5):983-1003, 1959. 
Sperk, G. and R.J. Baldessarini. "Stabilizing effect of sucrose on leakage 
of cytoplasm from rat brain synaptosomes in saline media." J. 
Neurochem. 28:1403-1405, 1977. 
Stock, J.P.P. and N. Dal~. t'Beta-adrenergic receptor blockade in cardiac 
arrhythmias." Br. med. J. 2:1230-1232, 1963. 
Street, J.A., J.G. Webb, P.S. Bright and T.E. Gaffney. "Accumulation, 
subcellular localization and release of propranolol from synaptosomes 
of rat cerebral cortex." J. Pharmac. expo Ther. 229(1):154-161, 
1984. 
Sugawara, K., N. Takami, S. Maemura, M. Niwa and M. Ozaki. "(:l-adreno-
ceptor blocking agents release catecholamines from rat adrenal 
medulla." Eur. J. Pharmac. 62:287-295, 1980. 
Surewicz, W.K. and W. Leyko. 
phospholipid membranes: 
spectroscopy studies." 
ttInteraction of propranolol with model 
monolayer, spin label and fluorescence 
Biochim. biophys. Acta 643:387-397, 1981. 
Tackett, R. L., J. G. Webb and P. J. Privitera. "Cerebroventricular 
propranolol elevates cerebrospinal fluid norepinephrine and lowers 
blood pressure." Science 213:911-913, 1981. 
Tarazi, R.C., H.P. Dustan and E.L. Bravo. "Haemodynamic effects of 
propranolol in hypertension: a review." Postgrad. med. J. 52(Suppl. 
4):92-100, 1976. 
Tauc, L. tfNonvesicular release of neurotransmitter." Physiol. Rev. 
62(3):857-893, 1982. 
++ Tsudzuki, T. "The Ca -dependent dissociation of "H-dopamine bound to 
acidic glycoprotein present in the synaptosomal cytoplasm of rat 
brain." J. Biochem. 93:599-606, 1983. 
Umbreit, W.W., R.H. Burris and J.F. Stauffer, eds. 
Biochemical Techniques. Minneapolis: Burgess, 
88 
Manometric and 
1972 , P . 146 . 
Uretsky, N. J. and L. L. Iversen. "Effects of 6-hydroxydopamine on 
catecholamine containing neurons in the rat brain." J. Neurochem. 
17: 269-278, 1970. 
Van Zwieten, P.A. and P.B.M.W.M. Timmermans. "Comparison between the 
acute hemodynamic effects and brain penetration of atenolol and 
metoprolol." J. cardiovasc. Pharmac. 1:85-96, 1979. 
Varon, S., H. Weinstein, T. Kakefuda and E. Roberts. "Sodium-dependent 
binding of y-aminobutyric acid by morphologically characterized 
subcellular brain particles." Biochem. Pharmac. 14:1213-1224, 1965. 
Vestal, R.E., D.M. Kornhauser and D.G. Shand. "Active uptake of 
propranolol by isolated rabbit alveolar macrophages and its inhibition 
by other basic amines." J. Pharmac. expo Ther. 214:106-111, 1980. 
Viveros, O.H., E.J. Diliberto, Jr. and A.J. Daniels. "Biochemical and 
functional evidence for cosecretion of multiple messengers from 
single and multiple compartments." Fed. Proc. 42(12):2923-2928, 
1983. 
Viveros, O.H., E.J. Diliberto, E. Hazum and K. Chang. "Opiate-like 
materials in the adrenal medulla: evidence for storage and secretion 
with catecholamines." Mol. Pharmac. 16:1101-1108, 1979. 
Vogel, S.A., S.D. Silberstein, K.R. Berv and I.J. Kopin. "Stimulation-
induced release of norepinephrine from rat superior cervical ganglia 
in vitro." Eur.J.Pharmac. 20: 308-311, 1972. 
Waggoner, A.S. "Dye indicators of membrane potential." Ann. Rev. Biophys. 
Bioenerg. 8: 47-68, 1979. 
Walle, T., E.C. Conradi, U.K. Walle, T.e. Fagan and T.E. Gaffney. "The 
predictable relationship between plasma levels and dose during chronic 
propranolol therapy." Clin. pharmac. Ther. 24:668-677, 1978. 
Warren, S.G., D.L. Brewer and E.S. Orgain. "Long term propranolol therapy 
for angina pectoriS." Am. J. Cardiol. 37:420-426, 1976. 
Webb, J.G., K.R. Berv and I.J. Kopin. "Induction of dopamine beta 
hydroxylase in superior cervical ganglia in organ culture." 
Neuropharmacology 14: 643-648, 1975. 
Weinstock, M., N.B. Thoa and I.J. Kopin. t'f3-adrenoceptors modulate 
norepinephrine release from axonal sprouts in cultured rat superior 
cervical ganglia." Eur. J. Pharmac. 47: 297-302, 1978. 
Weinstock, M., C. Weiss and S. Gitter. "Blockade of 5-hydroxytryptarnine 
receptors in the central nervous system by f3-adrenoceptor antagonists." 
Neuropharmacology 16:273-276, 1977. 
89 
Wideroe, T. and T. Vingander. "Propranolol in the treatment of migraine." 
Br. med. J. 2:699-701, 1974. 
Wilson, A.G., O.G. Brook, H.J. Lloyd and B.F. Robinson. "Mechanism of 
action of ~-adrenergic receptor blocking agents in angina pectoris: 
comparison of action of propranolol with dexpropranolol and practolol." 
Br. med. J. 4:399-401, 1969. 
Wolff, H.G. "Headache in the migraine syndrome." In: Headache and other 
head pain. New York: Oxford University Press, 1963, pp. 227-301. 
Wood, M.D. and M.G. Wyllie, "Critical assessment of noradrenaline uptake 
in synaptosomal preparations." Naunyn-Schmiedebergts Arch. Pharmac. 
322:129-135, 1983. 
Woosley, R.L., D. Kornhauser, R. Smith, S. Reele, S.B. Higgins, A.S. Nies, 
D.G. Shand and J.A. Oates. "Suppression of chronic ventricular 
arrhythmias with propranolol. tt Circulation 60(4):819-827, 1979. 
Wu, C.H. and T. Narahashi. "Mechanism of action of propranolol on squid 





" Z C 



















o e 24 
TIME IN CULTURE (HOURS) 
Figure 1. Uptake of 3H-norepinephrine by rat superior cervical 
ganglia after different periods of time in organ culture. Ganglia 
were incubated with 3H-norepinephrine for 30 minutes. Results 
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Figure 2. Frequency-dependent release of 3H-norepinephrine and 3H-propranolol from field-
stimulated cultured superior cervical ganglia of the rat. The stimulation parameters were: 
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Figure 3. Time-dependent release of 3H-norepinephrine and 3H-propranolol from field-
stimulated cultured superior cervical ganglia of the rat. The stimulation parameters were: 
10 rnA, 15 Hz and 4 msec. Results are mean values for groups of 5-6 ganglia. 
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Figure 4. The influence of extracellular calcium on 3H-norepi-
nephrine and 3H-propranolol release from field-stimulated cuI tured 
superior cervical ganglia of the rat. The stimulation parameters 
were: 10 rnA, 15 Hz, 4 msec. The ganglia were stimulated for 30 
seconds. Results are expressed as means ± S.E. of 4-5 determina-
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Figure 5. The effect of bretyliurn on 3H-norepinephrine and 3H-propranolol 
release from field-stimulated cultured superior cervical ganglia of 
the rat. The stimulation parameters were: 10 rnA, 15 Hz, 4 msec. 
Ganglia were stimulated for 30 seconds. Results are expressed as 
me ans ± S.E. of at least 5 determinations. ~'~Significant diffe r ence 































Figure 6. The effect of phenoxybenzamine on 3H-norepinephrine and 
3H-propranolol release from field-stimulated cultured superior 
cervical ganglia of the rat. The stimulation parameters were: 10 
rnA, 15 Hz, 4 msec. Ganglia were stimulated for 30 seconds. Results 
are expressed as means ± S.E. of at least 5 determinations. 
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Figure 7. The effect of reserpine on 3H-norepinephrine and 3H-
propranolol accumulation in cultured superior cervical ganglia of the 
rat. Results are expressed as means ± S.E. of 4-6 determinations. 
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Figure 8. The effect of reserpine on 3H-norepinephrine and 3H-propranolol 
release from field-stimulated cultured superior cervical ganglia of 
the rat. The stimulation parameters were: 10 rnA, 15 Hz, 4 msec. 
Ganglia were stimulated for 30 seconds. Results are expressed as 
means ± S.E. of 4-6 determinations. ** Significant difference from 
control at p < .001. 
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Figure 9. Electron micrograph of rat cortical synaptosomes following 
incubation in modified Krebs-Ringer buffer. Glutaraldehyde fixation, 




































Figure 12. Representative tracing of fluorescence changes of the potential-sensitive dye, 
diS-C
3
-(5), produced by elevated concentrations of potassium in the absence and presence 
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Figure 13. Time course of the accumulation of radioactivity by rat 
cortical synaptosomes during incubation at 30°C with 3H-propranolol 
(A) or 3H-atenolol (B). A drug concentration of 0.1 ~M was used in 
both cases. Each point represent the mean of 4 to 6 determinations. 
Vertical bars represent S.E. mean. (Used with the permission of 
Dr. J.A. Street.) 
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Figure 14. Time course of potassium-induced release of 3H-propran-
0101 from prelabelled rat cortical synaptosomes at 30o e. Synapto-
somes were preloaded by incubation with 3H-propranolol (0.1 ~M) for 
10 minutes. Each point represents the mean of 3 to 15 determinations. 
Vertical bars represent S.E. mean. 
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Figure 15. Time course of potassium-induced release of 3H-norepi-
nephrine from rat cortical synaptosomes at 30°C. Synaptosomes were 
loaded by incubation with 3H-norepinephrine (0.1 ~M) for 10 minutes. 
Each point represents the mean of 5 determinations. Vertical bars 
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Figure 16. Effects of alkali metal ions to promote 3H-propranolol 
release (A) and to depolarize synaptosomes (B). 3H-propranolol 
release was measured for one minute. Membrane depolarization is 
reflected as an increase in the intensity of dye (diS-C
3
-(S)) 
fluorescence, expressed as a percentage of the fluorescence 
observed at 100 mM external potassium. Each point represents the 
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Figure 17. Regression analysis of the relationship between the 
effects of ions to promote 3H-propranolol release from synaptosomes 
and the action of these ions to depolarize the synaptosomal membrane. 
Membrane depolarization is expressed as the intensity of dye (diS-C
3
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Figure 18. Effect of carbonyl-cyanide-m-chlorophenylhydrazone (CCCP) 
on potassium-induced release of 3H-propranolol (A) and 3H-atenolol (B) 
from prelabelled rat cortical synaptosomes at 30°C. 3H-propranolol 
release was measured for 1 minute and 3H-atenolol release for 2 
minutes. Results are expressed as the mean ± S.E. of 3 determinations. 
Statistically significant differences from control are indicated by 
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Effect of tetrodotoxin on veratridine-induced release 
of 3H-propranolol (A) and 3H-norepinephrine (B) from rat cortical 
synaptosomes. 3H-norepinephrine release was measured for 3 minutes. 
Each point represents the mean of 2 to 9 determinations. Vertical 
bars represent S.E. mean. Statistically significant differences 



















Figure 20. Time course of potassium-induced release of 3H-atenolol 
from prelabelled rat cortical synaptosomes at 30°C. Synaptosomes 
were preloaded by incubation with 3H-atenolol (1.0 ~M) for 20 
minutes. Each point represents the mean of 4 to 11 determinations. 
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Figure 21. Effect of tetrodotoxin on veratridine-induced release 
of 3H-atenolol from rat cortical synaptosomes. Each point represents 
the mean of 5 determinations. Vertical bars represent S.E. mean. 
Statistically significant differences from veratridine-induced 
release are indicated by * p < 0.01. 
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Figure 22. Effect of calcium on A23187-induced release of 3H-
norepinephrine from prelabelled rat cortical synaptosomes at 30°C. 
Each point represents the mean of 3 determinations. Vertical bars 
represent S.E. mean. Statistically significant differences from 










Figure 23. Effect of calcium on A23187-induced release of 3H-pro-
pranolol from prelabelled rat cortical synaptosomes at 30°C. Each 
point represents the mean of 3 to 5 determinations. Vertical bars 
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Figure 24. Effect of calcium on A23187-induced release of 3H-atenolol 
from prelabelled rat cortical synaptosomes at 30°C. 3H-atenolol 
release was measured for 3 minutes. Results are expressed as the 
mean ± S.E. of 3 to 5 determinations. Statistically significant 
differences from control are indicated by * p < 0.05. 














Figure 25. Possible cellular release mechanisms for transmitters 
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